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2. ABBREVIATIONS 
ACD allergic contact dermatitis 
AD atopic dermatitis 
AHR airway hyperresponsiveness 
APC antigen presenting cell 
BAL  bronchoalveolar lavage 
BMP  bone morphogenetic protein 
CCL  C-C family chemokine ligand 
CCR   C-C family chemokine receptor 
CD cluster of differentiation 
cDNA  complementary deoxyribonucleic acid 
CHS  contact hypersensitivity
Co-Smad common-partner Smad 
cpm counts per minute  
CTL cytotoxic T cell 
CXCL  C-X-C family chemokine ligand 
CXCR  C-X-C family chemokine receptor 
DC  dendritic cell 
DNA deoxyribonucleic acid 
DNFB 2,4-dinitrofluorobenzene 
DTH  delayed type hypersensitivity 
EC  epicutaneous 
ECM  extracellular matrix 
EGF epidermal growth factor 
ELISA  enzyme-linked immunosorbent assay 
ENA-78 epithelial cell-derived neutrophil attractant -78 
Foxp3  forkhead box P3   
GCP-2 granulocyte chemotactic protein -2 
HPF  high power field 
HPLC high-performance liquid chromatography 
I-309 inducible-309 
IFN  interferon 
Ig  immunoglobulin 
IL  interleukin 
IP-10  interferon inducible protein-10 
I-Smad inhibitory Smad 
I-TAC IFN- -inducible T-cell chemoattractant 
JNK Jun N-terminal kinase 
kDa  kilo Dalton 
KO  knock out 
LAP latency associated protein  
LC Langerhans cell 
LIX  lipopolysaccharide induced CXC chemokine 
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LLNA local lymph node assay 
LTBP latent TGF-  binding protein 
MAD mothers against decapentaplegic 
MAPK mitogen-activated protein kinase 
MCh  methacholine  
MCP monocyte chemoattractant protein 
MDC monocyte-derived chemokine 
MGG  May-Grünwald-Giemsa 
MH  mad homology 
MHC  major histocompatibility complex 
MIG  monokine induced by gamma interferon  
MIP-1   macrophage inflammatory protein 1-
MMP  matrix metalloproteinase 
mRNA  messenger ribonucleic acid 
MSA mouse serum albumin 
OVA  ovalbumin 
PAS  periodic acid Schiff 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
Penh  enhanced pause 
PI3K phosphatidylinositol-3-kinase 
PMN polymorphonuclear neutrophil leukocyte 
PP2A protein phosphatase 2A 
RANTES  regulated upon activation normally T-cell expressed and secreted 
RNA ribonucleic acid 
RQ   relative quantity 
R-Smad receptor activated Smad 
SDS sodium dodecyl sulfate 
SDF stromal cell-derived factor 
SMAD The SMAD proteins are homologs of both the drosophila protein, mothers 
against decapentaplegic (MAD) and the C. elegans protein SMA. The name 
is a combination of the two. 
SPF specific pathogen free 
TARC thymus- and activation-regulated chemokine 
T R(I) type I TGF-  receptor 
T R(II) type II TGF-  receptor 
T R(III) type III TGF-  receptor 
TCR T-cell receptor 
TGF-   transforming growth factor -
Th  T helper 
TMA trimellitic anhydride 
TNF  tumor necrosis factor 
WHO World Health Organization 
WT  wild type 
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3. ABSTRACT 
Transforming growth factor (TGF)-  is an important immunomodulatory and fibrogenic 
factor that regulates cellular processes in injured and inflamed skin. TGF-  signals are 
delivered from the cytoplasm to the nucleus by TGF-  signal transducers called Smads. 
Smad3 is a major signal transducer in TGF-  -signalling that controls the expression of 
target genes in the nucleus in a cell-type specific manner.  
In this thesis, the role of TGF- -Smad -signalling pathway using Smad3 -deficient mice in 
murine models of allergic diseases, atopic dermatitis, asthma and contact dermatitis was 
examined.  
Dermatitis was induced in mice by epicutaneous application of ovalbumin (OVA) applied 
in a patch to tape-stripped skin (I). The thickness of dermis was significantly reduced in 
OVA-sensitized skin of Smad3-/- mice. The defect in the dermal thickness accompanied 
with the decrease in the expression of mRNA for proinflammatory cytokines IL-6 and IL-
1  in the OVA-sensitized skin. In contrast, the number of mast cells was significantly 
increased in OVA sensitized skin of Smad3-/- mice and they also exhibited elevated levels 
of OVA-specific IgE.
The role of TGF- /Smad3 -signalling in cytokine homeostasis was studied in the airways 
of naive mice and for the regulation of bronchial hyperreactivity and inflammation using a 
murine model of asthma. Compared to wild type mice, naive (unmanipulated) Smad3-/- 
mice exhibited significantly increased levels of proinflammatory and Th2 cytokines as 
well as the Th2 associated transcription factor GATA-3 in the lung tissue and 
bronchoalveolar lavage (BAL). In the asthma model, mucin secretion and airway 
hyperresponsiveness (AHR) after allergen exposure were significantly increased in the 
Smad3-/- mice as compared to WT mice. OVA-specific IgE, IgG1 and IgG2a levels were 
increased in Smad3-/- and WT mice. IL-4 levels were equally elevated but IL-13 levels 
were decreased in the airways of OVA sensitized Smad3-/- mice compared to the controls.  
In the contact hypersensitivity studies (CHS), the skin and ears of Smad3 mice were 
treated with a contact allergen, oxazolone (III), or a respiratory allergen (IV), trimellitic 
acid anhydride (TMA). Topical exposure to oxazolone induced a significantly increased 
expression of CCL3/MIP-1  and CXCL5/LIX accompanied by increased neutrophil 
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infiltration in the skin of Smad3 deficient mice when compared to their wild type siblings. 
The mRNA expression for pro-inflammatory and Th2 cytokines were also significantly 
increased in Smad3-/- mice compared to wild type mice. Furthermore, topical exposure to 
oxazolone induced significantly increased expression of TGF-  and Foxp3 mRNA in 
Smad3-/- mice. However, Th1 cytokine IFN- , as well as Th1 type chemokines 
CXCL9/MIG and CXCL10/IP-10 were unaffected by the lack of Smad3, and the ear 
swelling responses to topically applied oxazolone were similar in Smad3 knockout mice 
as in wild type mice.  
Topical exposure to TMA, as well as oxazolone, promoted proinflammatory and Th2 
cytokine secretion in mice with a defect in TGF- /Smad3 -signaling. In addition, the 
exposure to TMA upregulated mRNA expression for Th1 cytokines. The expression of IL-
17 mRNA in the skin of TMA sensitized Smad3-/- mice was also increased pointing to an 
involvement of Smad3 in the progress of IL-17-induced tissue inflammation. TMA, like 
OXA, induced significantly increased expression of CCL3/MIP-1  and CXCL5/LIX in the 
skin of Smad3 deficient mice when compared to their wild type siblings.  
In conclusion, Smad3-pathway regulates allergen induced skin inflammation and systemic 
IgE antibody production in a murine model AD. The defect in Smad3 -signalling 
decreased Th2 cytokine (IL-13 and IL-5) mRNA expression in the lung, modulated 
allergen induced specific IgG1 response, and affected mucus production in the lung in a 
murine model of asthma. TGF-  / Smad3 -signalling contributed to inflammatory 
hypersensitivity reactions and disease progression via modulation of chemokine and 
cytokine expression and inflammatory cell recruitment, cell proliferation and regulation of 
the specific antibody response in a murine model of CHS. TGF-  modulates inflammatory 
responses - at least partly through the Smad3 pathway - but also through other 
compensatory, non-Smad-dependent pathways. In the future the Smad3 signalling 
pathway might be a potential target in the therapy of allergic diseases. 
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4. INTRODUCTION 
Allergic diseases, such as atopic dermatitis, asthma, and contact dermatitis are complex 
diseases influenced by both genetic and environmental factors. It is still unclear why 
allergy and subsequent allergic disease occur in some individuals but not in others. 
Although the reason for the increased prevalence of allergic diseases, especially in 
industrialized countries, is unknown, the improved hygiene and better infection control 
have been suggested to have had a potential influence on the development of allergy 
(Strachan 1989, von Mutius 2007). 
Activated Th2 lymphocytes and the involvement of cytokines such as IL-4, IL-5 and IL-13 
are responsible for the eosinophil activation and IgE production crucial in allergic 
inflammation (Spencer et al. 2008, Incorvaia et al. 2008). Reduced microbial exposures 
(or other environmental stimuli) in early life have been suggested to shift the polarization 
of allergen-specific T-cell memory towards the Th2 instead of the Th1 immune response 
(Chang and Pan, 2008). 
However, the disturbance of the Th1/Th2 balance cannot explain on its own the 
dysregulated immune system involved in allergy; in addition some other mechanisms may 
be involved by T-regulatory cells. Many types of T-regulatory cells have been identified,  
most of these are recognized for their production of IL-10 and transforming growth factor-
 (TGF- ). An immune suppression of the T-regulatory cells has been proposed to be 
involved in the Th2-skewed immune response among atopic individuals (Bach 2002, 
Romagnani 2004). It is known that allergy results from a breakdown of tolerance to 
allergens. Tolerance re-induction may be used as a tool since it can be considered as an 
immunotherapeutic in allergic diseases. An immunosuppressive cytokine, TGF-  is 
involved, in immunological tolerance and the regulation of the immune response to 
allergens (Akdis 2006, Taylor et al. 2006). 
TGF-  signals are delivered from the cytoplasm to the nucleus by TGF-  signal 
transducers called Smads. Smads are intracellular proteins, transcription factors of 42-65 
kDa in mass (Massague 1998, Moustakas et al. 2001). Smad3 is the crucial signal 
transducer in TGF-  -signalling (Wang et al. 2005) and it controls the expression of target 
genes in the nucleus in a cell type specific manner. Understanding the effects of the TGF-
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 signalling pathway in immune system and in disease models can help in elucidating the 
multilevel effects of TGF- . At present the role and the functions of Smad3 in allergy are 
largely unknown. In this thesis, the significance of the Smad3 signal transducer was 
investigated in the murine models of atopic dermatitis, asthma, and allergic contact 
reactions.
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5. REVIEW OF THE LITERATURE 
5.1 Allergy and allergens 
Allergy is defined as disease following a response by the immune system to an otherwise 
innocuous antigen (Janeway et al. 2005).  It is a hypersensitivity reaction, initiated by 
specific immunologic mechanisms (Johansson et al. 2004). The term hypersensitivity
describes objectively reproducible symptoms or signs initiated by exposure to a defined 
stimulus at a dose tolerated by normal persons (Johansson et al. 2004). Hypersensitivity 
can be antibody-mediated or cell-mediated.  
Hypersensitivity reactions have been classified into four types by Coombs and Gell 
(Coombs and Gell, 1963): type I responses are mediated by IgE, which induces mast cell 
activation. Type II (directed against cell-surface or matrix antigens) and type III reactions 
(directed against soluble antigens) are mediated by IgG. IgG antibodies to environmental 
antigens are commonly found without causing any signs or symptoms (Johansson et al.
2004).
In the non-IgE-mediated allergy, also allergen-specific lymphocytes can mediate the 
inflammation, as is the case in allergic contact dermatitis. Type IV hypersensitivity 
reactions are T-cell mediated and can be subdivided into three groups depending on the 
type of the cell reacting (T helper1, T helper 2 or  cytotoxic T cells)( Janeway et al. 2005).
Allergic inflammation is the inflammation produced in sensitized subjects after exposure 
to a specific allergen(s). A single allergen exposure produces an acute reaction, known as 
an early-phase reaction or a type I immediate hypersensitivity reaction, in many cases 
followed by a late-phase reaction. If the exposure to allergen is persistent or repetitive, 
chronic allergic inflammation develops, with associated tissue alterations (Galli et al.
2008). In predisposed individuals, initial exposure(s) of professional antigen-presenting 
cells to allergen causes the activation of allergen-specific Th2 cells and IgE synthesis, 
known as allergic sensitization. Subsequently exposures to allergen lead to the infiltration 
of inflammatory cells causing early allergic responses and late allergic responses. Early-
phase reaction is an IgE-mediated and it can occur within minutes of allergen exposure. 
Reactions can be localized (for example acute asthma attacks, urticaria, gastrointestinal 
reactions in food allergies) or systemic (anaphylaxis). IgE bound to Fc RI on mast cells 
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and basophils is crosslinked by allergen resulting in the release of the cells' diverse 
preformed and newly synthesized mediators (histamine, cysteinyl leukotrienes and 
cytokines) leading to vasodilation, increased vascular permeability with oedema and acute 
changes in the function of affected organs (urticaria, vomiting, bronchoconstriction, 
airway mucus secretion). The released mediators also cause the infiltration and the 
activation of inflammatory cells which contribute to the development of late-phase 
reactions (Galli et al. 2008, Holgate and Polosa, 2008). Chemokines released by mast cells 
and other cell types direct the recruitment of inflammatory cells that contribute to the late 
allergic response characterized by accumulated Th2 cells and eosinophils. Cells release 
pro-inflammatory mediators including cysteinyl leukotrienes and basic proteins (cationic 
proteins, eosinophil peroxidase, major basic protein and eosinophil-derived neurotoxin, 
cytokines IL-3, IL-5, IL-13). Th1-cell responses might also be responsible in some 
pathogenic features in chronic forms of atopy, including epithelial apoptosis and smooth-
muscle-cell activation (Holgate and Polosa, 2008). Late-phase reaction develops 2-6 h, 
peaks 6-9 h after allergen exposure and resolves in 1-2 days. Skin late-phase reactions 
involve oedema, pain, warmth and erythema (redness). In the lungs, these reactions are 
characterized by airway narrowing and mucus hypersecretion. The local recruitment and 
activation of Th2 cells, eosionophils, basophils and other leukocytes occurs as well as 
persistent mediator production by resident cells (such as mast cells). Mediators that initiate 
late-phase reactions are thought to be derived from T cells (either resident or recruited to 
the sites of allergen challenge) that recognize allergen-derived peptides or resident mast 
cells activated by IgE and allergen (Galli et al. 2008). Regulatory T cells may suppress 
Th2 responses by secreting TGF-  and IL-10. In chronic allergic inflammation large 
numbers of innate and adaptive immune cells (in the form of leukocytes) are present at the 
affected site. In addition, there are substantial changes in the extracellular matrix and 
alterations in the number, phenotype and function of structural cells in the affected tissues 
(Galli et al. 2008). 
Allergens are antigens that elicit hypersensitivity or allergic reactions (Janeway et al.
2005). An antigen is any molecule that can bind specifically to an antibody or T-cell 
receptor. The name arises from the ability to generate antibodies. Allergens can enter the 
body via the skin, airways or gastrointestinal tract.
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5.1.1 Proteins 
Protein allergens originate from proteins with a variety of biological functions, including 
proteases, ligand-binding proteins, structural proteins, pathogenesis-related proteins, lipid 
transfer proteins, and calcium-binding proteins (Chapman et al. 2007, Russano et al.
2008). Biological function may directly influence the development of IgE responses and 
lead to allergy and may initiate inflammatory responses in the lung that are associated with 
asthma (Chapman et al. 2007, Shakib et al. 2008). According to the protein family 
database analysis, the universe of protein allergens comprises more than 120 distinct 
protein families (Chapman et al. 2007).
5.1.2 Chemicals 
5.1.2.1 Contact chemical allergens 
Contact allergens are usually of small molecular weight and lipophilic enabling them to 
penetrate the outer skin layers. Due to their small size, they must bind to larger proteins to 
become allergenic (haptens; from the Greek verb haptein, to fasten). Contact allergens can 
be different types of compounds: metals (nickel, cobalt, chromate), preservatives 
(formaldehyde, parabens, methyl(chloro)isothiazolinone), fragrances, medicaments 
(neomycin, benzocaine, ethylene diamine), adhesives (epoxy resin), rubber 
(mercaptobenzathiazole, N-isopropyl-N-phenylediamine), plants (Basketter et al, 1999). 
Contact allergens commonly have irritant properties. In order to achieve effective skin 
sensitisation, a chemical allergen is transported by cutaneous dendritic cells from the skin 
in sufficient amounts and in an immunogenic form to the draining lymph nodes. In the 
draining lymph nodes, responsive T lymphocytes become activated and are induced to 
divide and differentiate. 
5.1.2.2 Respiratory chemical allergens 
While many chemicals are known to induce allergic contact dermatitis, fewer chemicals 
like diisocyanates, acid anhydrides (such as trimellitic anhydride, TMA), platinum salts 
and reactive dyes are associated instead with sensitisation of the respiratory tract (Botham 
et al. 1989, Briatico-Vangosa et al. 1994).
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Chemical respiratory allergens are associated with selective Th2-type immune responses, 
whereas contact allergens, which are considered not to cause sensitisation of the 
respiratory tract, stimulate immune responses of preferential Th1 cell activation in mice 
(Kimber and Dearman, 1997). 
5.2 Molecular basis of allergic reactions 
The immune system consists of the adaptive and innate elements of the immune response. 
Innate immunity is responsible for the immune responses in early phases of the infection. 
It is present in all individuals at all times and it does not increase with repeated exposure 
to a given pathogen. Adaptive immunity or adaptive immune response is the response of 
antigen-specific lymphocytes to an antigen, developing also an immunological memory. 
In contrast to innate immunity, adaptive immune responses are generated by clonal 
selection of antigen-specific lymphocytes (Janeway et al. 2005). 
Innate immune responses appear to be less critical in determining the outcomes of allergic 
diseases compared with their protective role against pathogens. However, the development 
of the adaptive immune responses may be affected by the interaction of the innate 
response to allergens. The cells responding in innate immunity are often present in the 
likely sites of allergen exposure, including skin and respiratory tract (Leggat et al. 2008).
5.2.1 Lymphocytes and antigen presenting cells
Lymphocytes are crucial in the development of the immune response in allergy. 
Lymphocytes are divided to two major types, T and B lymphocytes.  
B cells are generated in the bone marrow throughout life. The antigen receptor on B 
lymphocytes, the B cell receptor, is a cell-surface immunoglobulin. After activation by an 
antigen, B cells differentiate into cells producing antibody molecules of the same antigen 
specificity as this receptor (LeBien and Tedder, 2008).  
T cells develop in the thymus. They are defined by heterodimeric receptors ( :  or :
heterodimeric receptor) associated with the proteins of the CD3 complex. (Janeway et al.
2005). Adaptive immune responses are initiated by T cells bearing alpha-beta ( - ) T cell 
antigen receptors (TCRs), which make up the majority of T cells. 
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Two classes of -  T lymphocytes, CD4 and CD8, are involved in adaptive immune 
responses. They are distinguished by the expression of the cell surface co-receptor, their 
interaction with different MHC molecules, and by their different functions. CD4+ T cells, 
T helper (Th) cells recognize antigen presented by class II MHC molecules, present only 
on antigen-presenting cells (APCs), such as dendritic cells, B cells, and macrophages. 
APCs take up the antigen and process it (proteins into peptides) in endocytic vesicles, 
which are presented on the cell surface bound to class II MHC molecules (Arnold and 
Mannie, 1999, Nolte-'t Hoen et al. 2004). CD8 cytotoxic T (Tc) cells recognize antigen 
presented by class I MHC molecules (Cohn and Ray, 2003). 
In the peripheral lymphoid tissues (lymph nodes, spleen, mucosal lymphoid tissues), T 
cells encounter the foreign antigens bearing APCs. Dendritic cells are the primary APCs 
that activate naive T cells. The processing of antigen leads to the maturation of immature 
DCs to mature DCs, which then leave the mucosal surface and migrate to local lymphoid 
tissues. After contacting its specific antigen on an APC in the peripheral lymphoid tissue, 
the CD4+ T cell stops migrating back into the bloodstream. Two signals are required for 
the initiation of T cell activation: 1) TCR recognition of an MHC class II peptide and 2) a 
simultaneous co-stimulatory signal delivered by the same APC. Subsequently, the T cell 
enters the G1 phase of the cell cycle and starts producing interleukin-2 (IL-2), which is an 
essential T cell autocrine growth factor stimulating the T cell to go through the cell cycle 
and to perform clonal expansion (Cohn and Ray, 2003). The result is a population of 
effector cells with the identical TCR specificity to the parental cell. If a CD4+ T cell 
recognizes its specific antigen on an APC (signal 1) without a co-stimulatory signal, the 
cell becomes anergic or unresponsive because it is not able to proliferate due to the lack of 
IL-2 production (DeSilva et al. 1991). 
5.2.2 Other inflammatory cells 
Mast cells, basophils and eosinophils are essential cellular components of allergic 
inflammation. 
The mast cell is a tissue-based inflammatory cell of bone marrow origin that responds to 
signals of innate and acquired immunity with immediate and delayed release of histamine 
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and other inflammatory mediators to secrete cytokines such as TNF-  thereby initiating a 
local inflammatory response. Mast cells are linked to the pathogenesis of allergic diseases 
via their ability to be activated through Fc RI-bound antigen-specific IgE. Mast cell 
activation occurs only when the bound IgE is cross-linked by multivalent antigen. This 
signal activates the mast cell to release in seconds the contents of its granules. 
Degranulation releases the stored histamine, causing a local increase in blood flow and 
vascular permeability leading quickly to an accumulation of fluid and blood proteins, 
including antibodies, in the surrounding tissue. Soon, during the next few minutes to a few 
hours, polymorphonuclear leukocytes infiltrate and, later, also macrophages, eosinophils, 
and effector lymphocytes (Janeway et al. 2005). Mast cells increase several-fold in 
association with IgE-dependent immediate hypersensitivity reactions, including urticaria 
and asthma, connective tissue disorders, and infectious diseases (Prussin and Metcalfe, 
2006).
Mast cells produce pre-formed mediators, such as histamine and serine proteases, newly 
synthesized lipid mediators, such as prostaglandin (PG) D2 and the leukotriene (LT) C4.
Skin mast cells produce more PGD2 than LTC4, whereas the opposite is produced by mast 
cells from the lung. PGD2 and LTC4 are bronchoconstrictors and PGD2 is a neutrophil 
chemoattractant (Prussin and Metcalfe, 2006). 
TNF- , IL-4, IL-5, IL-6, IL-8 are the major cytokines produced by mast cells. Mast cells 
also produce chemokines, such as CCL3 (macrophage inflammatory protein 1 ) (Prussin 
and Metcalfe, 2006). Participation of mast cell activation in the initiation of the immediate 
hypersensitivity reaction occurs in several forms, e.g. in the skin as erythema, edema, and 
itch; in the upper airways as sneezing, rhinorrhea, and mucous secretion; in the lungs as 
cough, bronchospasm, edema, and mucous secretion. There are also a late-phase reactions, 
i.e. the initial symptoms can be followed 6 to 24 hours later by leukocytic influx and a 
persistent edema. Mast cells might contribute to the downregulation of the allergic 
response producing and the release of IL-1 receptor antagonist, heparin, and other 
molecules with anti-inflammatory properties (Prussin and Metcalfe, 2006). 
Basophils are granulocytes sharing common features with mast cells, such as Fc RI
expression, Th2 cytokine expression, and histamine release. After activation, basophils 
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rapidly start to produce IL-4 and IL-13, indicating that they play a role in allergic 
inflammation (Prussin and Metcalfe, 2006).  
Eosinophils are granulocytic leukocytes that are produced in bone marrow from 
pluripotential stem cells. Eosinophils are primarily found in tissues, especially in the 
connective tissue immediately underneath respiratory, gut, and urogenital epithelium 
(Janeway et al. 2005). It has been estimated that in humans the eosinophil tissue/blood 
ratio is about 100:1 (Kita et al. 2003). The specific localisation of eosinophils, as well as 
mast cells, in mucosal tissues refers to the role in mucosal immune response. 
Tissue eosinophilia is often found at inflammatory sites and peripheral blood eosinophil 
counts become increased in allergic disease and asthma. Eosinophils are thought to play a 
central role in allergic disease and asthma, with eosinophil mediators, such as cytokines 
and major basic protein (MBP), evoking mucosal inflammation and consequent bronchial 
hyperresponsiveness in asthma (Adamko et al. 2003). 
5.2.3 Immunoglobulin E  
IgE is an immunoglobulin isotype composed of two types of protein chain: heavy chains 
and light chains. Antibodies of different immunoglobulin isotype are produced in an 
immune response in distinct places and have distinct effector functions. IgE antibody is 
present only at very low levels in blood or extracellular fluid but is bound avidly by 
receptors on mast cells that are found just beneath the skin and mucosa, and along blood 
vessels in connective tissue. Antigen binding to this cell-associated IgE triggers mast cells 
to release powerful chemical mediators that induce reactions, such as coughing and 
sneezing (Janeway et al. 2005). Two signals are required to trigger IgE synthesis. Signal 1 
is provided by IL-4 or IL-13, which activate transcription at a specific immunoglobulin 
locus. The engagement of CD40 on B cells by the CD154 expressed on T cells provides 
the second signal required for switching on IgE. T cells are the principal source of these 
signals (Cameron and Vercelli, 2003). 
Most patients with allergic symptoms from mucosal membranes in the airways and 
gastrointestinal tract, express IgE antibodies to allergens and the allergy is said to be IgE-
mediated. Total serum IgE concentrations tend to be higher in allergic individuals 
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compared to nonallergic adults and children, but the diagnostic relevance is limited as a 
screening test for allergic disease (Klink et al. 1990, King et al. 2004). Allergen-specific 
IgE antibodies in atopic individuals originate from a broad variety of B cells reflecting the 
activation of multiple B-cell clones during allergen sensitization (Eibensteiner et al. 2000). 
5.2.4 Cytokines and chemokines 
Cytokines are proteins made by cells that influence the behavior of other cells. They 
function via specific cytokine receptors on the cells that they affect (Janeway et al. 2005). 
Cytokines participate in the regulation of immune responses by regulating critical cell 
functions, i.e. growth, differentiation and activation. Cytokines are involved in antigen 
presentation, bone marrow differentiation, cellular recruitment and activation, adhesion 
molecule expression, and acute-phase responses (Borish and Rosenwasser, 2003).
Chemokines are small chemoattractant proteins that stimulate the migration and activation 
of cells, especially phagocytic cells and lymphocytes (Janeway et al. 2005). The family of 
chemokines consists of around 50 small proteins. Four chemokine groups have been 
classified on the basis of the arrangement of their amino-terminal cysteine residues. Most 
of the chemokines belong to the CC or CXC classes, where the two N-terminal cysteines 
are adjacent or have a single amino acid separating them, respectively (Zlotnik and 
Yoshie, 2000). A C class has a single amino-terminal cysteine and in the chemokines of a 
CX3C class the two cysteines are separated by three residues (Bazan et al. 1997). 
20
Table 1 Common cytokines and their effects in allergic diseases.
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to airway remodeling. 
 MHC class II  
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                     Th2 CELL    IgE 
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 Th17 CELL                TNF- , IFN-
    IL-17  
   MUCUS 
   EPITHELIAL CELL 
 FIBROBLAST 
  SMOOTH MUSCLE CELL 
   BLOOD VESSEL 
Figure 1 Mechanisms of allergic inflammation reaction. The activation of allergen-specific 
 Th2 cells and IgE synthesis by exposure of professional antigen-presenting cells 
 (APCs) to allergen in predisposed individuals. Subsequent exposures to allergen 
 cause inflammatory cell recruitment and activation and mediator release. Within 
 minutes of contact with allergen, IgE-sensitized mast cells degranulate releasing 
 mediators (histamine, cysteinyl leukotrienes, cytokines) in sensitized individuals. 
 Chemokines released by mast cells and other cell types direct the recruitment of 
 inflammatory cells contributing to the late allergic response which is characterized 
 by influx of eosinophils and Th2 cells. These cells secrete more inflammatory 
 mediators, cytokines and chemokines.Regulatory T (Treg) cells are able to suppress 
 Th2-cell responses by inhibitory cytokines IL-10 and TGF- . Th17 cells secrete IL-17, 
 which participates in the neutrophilic inflammatory events during disease 
 exacerbation and in tissue remodelling (modified from Holgate and Polosa, 2008). 
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Leukocytes possess cell-surface sensors for chemokines. Chemokines signal through G 
protein-coupled receptors and the repertoire of 19 receptors are differentially expressed on 
leukocytes depending on the type of leukocyte and its maturation stage. Several different 
chemokine receptors may be expressed at any one time, and these receptors can be broadly 
divided into two groups: those constitutively expressed by leukocytes and those which 
under inflammatory conditions are induced via receptor activation (Pease and Williams, 
2006). Selective blocking of chemokine receptor by small-molecule antagonists represents 
a putative target with therapeutic significance since it may be possible to suppress the 
recruitment of particular leukocyte types in an allergic reaction.
5.3 Atopy, allergic skin diseases and asthma 
5.3.1 Atopy 
Atopy is a personal and/or familial tendency, appearing usually in childhood or 
adolescence, to become sensitized and produce IgE antibodies in response to ordinary 
exposures to allergens, usually proteins. As a consequence, these atopic individuals can 
develop the characteristic symptoms of asthma, rhinoconjunctivitis, or eczema (Johansson 
et al. 2004). Atopy is a clinical definition of an IgE-antibody high-responder; it describes 
the genetic predisposition to become IgE-sensitized to allergens commonly occurring in 
the environment and to which everyone is exposed but to which a prolonged IgE-antibody 
response is not produced in the majority of the population (Johansson et al. 2004). Atopic 
diseases have recently increased to the extent that they can be viewed as an epidemic 
(Holgate 1999, Umetsu et al. 2002). For example, the incidences of three common 
syndromes of atopic origin (Johansson et al. 2001), asthma, atopic dermatitis and hayfever 
(allergic rhinitis), have almost doubled in industrialized countries over the past two 
decades (Umetsu et al. 2002, Cookson 1999). As many as 40 % of people in Western 
populations are now atopic (Janeway et al. 2005).
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Table 2 The cellular distribution of chemokine receptors and their principal ligands 
in allergic disease (modified from Pease and Williams, 2006). 




















B lymphocyte CXCR3, CXCR4  
Eosinophil CCR1, CCR3, CXCR4  
Monocyte CCR1, CCR8, CXCR4  
Basophil CCR1, CCR3, CCR4,
CXCR4
Mast cell CCR1, CCR3, CCR4, 
CXCR3, CXCR4 
Dendritic cell CCR1, CCR4, CXCR4  
I-309, inducible-309; IP-10, IFN- -inducible protein-10; I-TAC, IFN- -inducible T-cell 
chemoattractant; MCP, monocyte chemoattractant protein; MDC, monocyte-derived 
chemokine; Mig, monokine induced by IFN- ; MIP, macrophage inflammatory protein; 
RANTES, regulated upon activation, normal T cell expressed and secreted; SDF, stromal 
cell-derived factor; TARC, thymus- and activation-regulated chemokine. 
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5.3.2 Atopic dermatitis 
Atopic dermatitis (AD) is a common chronic inflammatory skin disease characterized by 
dry, inflamed and itchy skin (Hanifin and Rajka, 1980). Various susceptibility genes, host 
environments, infectious agents, defects in skin barrier function, and immunologic 
responses interact in the pathophysiology of AD (Novak et al. 2003). One typical 
characteristic of AD skin inflammatory responses is the activation of T lymphocytes, 
dendritic cells, macrophages, keratinocytes, mast cells, and eosinophils (Akdis et al.
2006). AD usually starts in early childhood and its prevalence has been increasing during 
recent years in parallel with other atopic conditions, i.e. asthma, rhinitis and allergies. It is 
believed that both genetic and environmental factors play an important role in developing 
of atopic dermatitis (Spergel and Paller, 2003; Foroughi et al. 2005; Linneberg et al.
2006).
Most patients with AD have elevated levels of serum IgE and specific IgE antibodies to 
environmental allergens are evidence of the important role played by allergens in AD. The 
initial event in the development of allergic disease is the generation of allergen-specific 
CD4+ Th cells (Romagnani, 2004). In the acute phase of AD, skin lesions show a marked 
infiltration with the presence of activated CD4+ T cells within the epithelium.  Th2 cells, 
once generated, characterize the inflammatory response expressing mRNA for Th2-type 
cytokines, IL-4, IL-5 and IL-13. Th2-associated cytokines are thought to induce allergen-
specific IgE production by B cells, thereby promoting the sensitization to allergen. Th2 
cytokines also induce the development and recruitment of eosinophils, production of 
mucus, and the contraction of smooth muscle (Romagnani, 2004). 
However, in the chronic phase of the disease, Th1-type cytokines become highly 
expressed, with the IL-12 and IFN-  mRNA -expressing cells predominating over Th2 
cells (Fiset et al. 2006, Grewe et al. 1998, Grewe et al. 1998). Th1 cells might also 
effectively contribute to the effector phase in allergic diseases (Trautmann et al. 2000, 
Trautmann et al. 2002) or, alternatively, dampen allergic inflammation, depending on the 
stage of the inflammation or on the disease model (Finotto et al. 2002). The maintenance 
of chronic AD also involves the production of the Th1-like cytokines, as well as 
remodelling-associated cytokines, such as TGF- 1 and IL-11, expressed preferentially in 
the chronic state of the disease (Toda et al. 2003). The severity of AD has been connected 
to the amount of thymus and activation-regulated cytokine levels (Hijnen et al. 2004). 
Supporting the migration of Th1 cells toward the epidermis, an intense upregulation of 
several chemokines, such as IFN- -inducible protein 10, monokine induced by IFN- , and 
IFN- -inducible  chemoattractant (Klunker et al. 2003), and fractalkine (Echigo et al.
2004), in keratinocytes has been demonstrated. The levels of macrophage-derived 
chemokine and thymus and activation-regulated cytokine are elevated in AD patients 
(Leung et al. 2004). These proteins also mediate the selective recruitment of Th2-cells 
expressing CCR4. In addition, upregulation of monocyte chemoattractant protein 4, 
eotaxin, and RANTES, participate in promoting the infiltration of macrophages, 
eosinophils, and T cells into acute and chronic AD skin lesions (Taha et al. 2000). 
In addition to Th1 and Th2 cells, a subtype of T cells, regulatory-suppressor T cells 
(Tregs) with immunosuppressive functions and a cytokine profile distinct from either Th1 
or Th2 cells have been identified. Treg cells have been shown to inhibit the development 
of allergic Th2 responses (Cottrez et al. 2000). 
   Th1      Th2                   Treg      
     
IFN-   IL-4                 TGF-
IL-12  IL-5                 IL-10 
TNF-   IL-9 
  IL-13 
Figure 2  Typical cytokines produced by Th1, Th2 and Treg cells. By direct secretion of 
cytokines, cells modulate the immune reaction at the site of inflammation. 
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5.3.3 Contact hypersensitivity 
Allergic reactions consist usually of two phases: the immediate reaction and delayed-type 
reaction. The hypersensitivity reactions that occur within minutes of exposure to antigen, 
are called immediate hypersensitivity reactions and are antibody mediated. The delayed-
type hypersensitivity is a form of cell-mediated immunity elicited by the antigen in the 
skin and this is mediated by CD4 Th1 cells. The reaction appears hours to days after 
antigen is injected. Thus, a contact hypersensitivity reaction is a form of delayed-type 
hypersensitivity in which T cells respond to antigens that are introduced by contact with 
the skin (Janeway et al. 2005). In this thesis, the focus was on the cell mediated, chemical 
induced delayed-type hypersensitivity reaction, allergic contact dermatitis.  
5.3.3.1. Allergic contact dermatitis 
Contact dermatitis can be classified into the type IV hypersensitivity reaction, delayed-
type hypersensitivity, reaction according to the classification by Coombs and Gell 
(Coombs and Gell, 1963). Tissue damage is evoked by Th1 cells activating macrophages 
or directly by cytotoxic T cell (CTL). A general view is that CHS is mediated by IFN-
producing CD8+ T cells, while IL-2, IL-4 and IL-10 producing CD4+ T cells regulate the 
response.
Induction phase, sensitization, antigen recognition (afferent phase)
A hapten is a low-molecular-weight, chemically reactive, lipid-soluble molecule that 
crosses the stratum corneum. In the skin, it covalently binds to carrier proteins; cell 
surface or structural proteins on various cells (e.g. Langerhans cells (LC), keratinocytes) 
to form a hapten-carrier complex, the antigen. The antigen is processed by dendritic cells, 
known as Langerhans cells, at the site of epidermal penetration. The antigens are first 
digested into small peptides that bind to class II MHC molecules. Then, the peptide 
antigen/MHC complex is transported to the LC surface membrane. The antigen-bearing 
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LCs migrate from the skin, through the efferent lymphatics into the regional draining 
lymph nodes. LCs present the antigen to naive CD4+ helper T lymphocytes. Specific T 
cells subsequently proliferate clonally in the paracortical region of the lymph nodes. 
Finally, effector and memory T cells are released into the circulation (Mydlarski et al.
2003).
Elicitation phase, challenge (efferent phase)
During the elicitation phase, a sensitized individual is re-exposed to a hapten and the 
hapten-carrier complex is formed again. However, in this situation, the antigen is 
presented by LCs in the epidermis, dermis, and regional draining lymph nodes. Clonal 
proliferation of specific T lymphocytes follows the recognition of the peptide 
antigen/MHC complex by effector and memory T cells. Resident and activated cells 
release a barrage of cytokines and chemokines leading to inflammatory reaction within 48 
hours after the re-exposure to the contact allergen (Cavani et al. 2000, Cavani et al. 2003, 
Mydlarski et al. 2003). 
Irritants such as sodium dodecyl sulfate (SDS) cause keratinocyte damage and 
mononuclear cell infiltration. However, in contrast to haptens, they do not activate the 
immune cascade via the antigen presentation pathway.  
5.3.4 Asthma 
Allergic asthma results from immunologic reactions. IgE antibodies participate in the 
initiation of most allergic asthma cases (Johansson et al. 2004). Asthma can be classified 
into type I or type IV hypersensitivity reactions according to the classification by Coombs 
and Gell (Coombs and Gell, 1963). The type I type is characterized by IgE-mediated 
inducing mast cell activation.   
Allergic asthma is a complex multifactorial disorder characterized by variable and 
reversible degrees of airway bronchoconstriction, hyperresponsiveness, mucus production, 
inflammation, and remodelling of the airways. Remodelling, as a feature of asthma, alters 
the size, mass or number of tissue components which occur in and around the trachea, 
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bronchi and bronchioles in the airways in response to injury and/or inflammation (Folli et 
al. 2008). CD4+ Th2 -type cells, which secrete IL-4, IL-5, and IL-13 are thought to 
contribute to the pathophysiological features of asthma. The inflammatory reaction is 
characterized by the influx of eosinophils, macrophages, neutrophils, CD4+ Th, and T 
cytotoxic (Tc) lymphocytes, mainly of type 2 cytokine phenotype (Th2 and Tc2) into 
airway epithelium and bronchial fluids (Henderson and Lodewick, 2003, Holgate, 2008). 
Cytokines, chemokines, adhesion molecules mediate airway inflammation and remodeling 
(Passalacqua and Ciprandi, 2008). 
5.4. Experimental models in allergy research
Asthma 
Sensitization to various allergens and following airway challenge with the specific 
allergen can produce the characteristic immunological, physiological, and pathological 
features of asthma in several species, including the mouse, rat, rabbit, guinea pig, dog, and 
nonhuman primates (Henderson and Lodewick, 2003). The timing, challenge, location, 
and type of allergen are important factors to be considered in selecting the experimental 
animal model. Several protocols describing the administration of ovalbumin (OVA) and 
other allergens (e.g. dust mite and fungal proteins) to induce allergen-specific pulmonary 
disease in animals have been described. Mouse develops IgE-mediated allergic responses 
and methacholine-induced changes in lung physiology, which mimic several aspects of 
human airway disease (Henderson and Lodewick, 2003). 
Asthma models in mouse are typically short-term or long-term models. In the long-term 
model of chronic allergic airway inflammation, there is the development of fibrosis and 
airway remodeling. In this thesis, a short-term model was used.  
In short-term models, mice are sensitized by intraperitoneal injection of an allergen (e.g. 
OVA) in alum adjuvant and mice are challenged with the specific allergen administered 
by aerosol, intratracheally, or intranasally. The repeated airway challenges with specific 
allergen are continued usually several weeks. Nonsensitized control mice are treated with 
alum alone via intraperitoneal injection, and only saline by airway administration. Airway 
administration of OVA promotes a Th2 phenotype in lymphocytes and these cells 
infiltrate the lungs of OVA-treated mice so that increased levels of total and OVA-specific 
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IgE can be detected. OVA-sensitized/challenged mice display mucus hypersecretion, 
eosinophilia and other inflammatory mediators in bronchoalveolar lavage (BAL) 
(Henderson and Lodewick, 2003). Allergen sensitization results in AHR, which can be 
measured by in vivo whole-body plethysmography (non-invasive technique). The degree 
of bronchoconstriction is calculated as enhanced pause (Penh), a dimensionless value, a 
junction of the proportion of the pressure signal from inspiration and expiration and of the 
timing of expiration (Hamelmann et al. 1997). The genetic background of the mouse is an 
important factor, since significant differences are observed in the ventilatory response 
between different mouse strains (Tankersley et al. 1994). 
AD
One of the earliest animal models of AD was the NC/Nga mouse. The animals have been 
reported to develop spontaneously AD-like eczematous skin lesions when kept in an air-
uncontrolled conventional room but not when maintained under specific pathogen-free 
(SPF) conditions (Matsuda et al. 1997). The clinical symptoms - itching, erythema, 
scaling dryness begin at the age of eight weeks. 
In murine model of protein induced atopic dermatitis, repeated epicutaneous sensitization 
with ovalbumin (OVA) has been shown to cause thickening of epidermis and dermis, 
infiltration of T cells and eosinophils and elevated levels of IL-4, IL-5, IFN-  mRNA, and 
airway hyperresponsiveness. The model can be developed in both BALB/c and C57BL/6 
mouse strains (Spergel et al. 1998).
Transgenic and knockout mice form the third group of murine models of AD. IL-18-
transgenic mice have been shown to develop AD-like skin lesions at about six months 
after birth under SPF conditions (Konishi et al. 2002). 
Contact hypersensitivity
Murine models of dermal sensitization have been described (Dearman and Kimber, 1999, 
Regal et al. 2001). The significance of the mouse ear swelling test, first described by Gad 
et al, is to identify potential contact allergens on the basis of challenge-induced increases 
in the ear thickness in a sensitized animal (Gad et al 1986). A different strategy is used in 
the local lymph node assay (LLNA), a murine model, which is capable of detecting low 
molecular weight chemicals that cause contact hypersensitivity (ICCVAM, 1999, Sailstad 
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et al. 2001). In the standard LLNA assay, mice are treated topically on the back of both 
ears with a test substance for three days. Following two days of rest, the initiation of the 
hypersensitivity response is tested by injecting 3H-thymidine into a tail vein, and then 
measuring the levels of radioisotope incorporated into the DNA of the cells of the lymph 
nodes draining the ears (Piccotti et al. 2006). Most, but not all, low molecular weight 
chemical allergens (both contact and respiratory) induce lymph node activation (Dearman 
et al. 1992). Those chemicals able to provoke a three-fold or greater increase in the 
proliferation of the draining lymph node cells compared with concurrent vehicle controls 
are classified as skin sensitizers (Piccotti et al. 2006). Chemical allergens have been 
differentiated from irritants by measuring the relative percentages of T and B cells in 
draining lymph nodes by flow cytometry (Gerberick et al. 2002). 
It has been difficult to distinguish chemicals that cause respiratory hypersensitivity from 
the larger group of contact sensitizers. Contact hypersensitivity has been associated with 
the elaboration of Th1 cytokines without any increase in IgE, whereas respiratory 
hypersensitivity responses evoke increased Th2 cytokines and total serum IgE. This seems 
to be true with at least some chemicals, e.g. trimellitic anhydride (TMA) and 2,4-
dinitrofluorobenzene (DNFB) (Dearman and Kimber, 1991,1992).  
5.5. Transforming growth factor -  in allergic diseases 
Transforming growth factor -  (TGF- ) is a multifunctional protein with widely diverse 
activities. Although much is known about its structure, expression, function, and 
receptors, the mechanisms of action and its role in allergy is still largely unknown.
5.5.1. Transforming growth factor -
TGF-  first came to attention in 1981 as a 25 kD factor which was capable of inducing the 
growth of rodent fibroblasts in the presence of a cofactor, epidermal growth factor (EGF) 
(Moses et al. 1981, Roberts et al. 1981). TGF- 1 belongs to a transforming growth factor-
beta superfamily, which consists of multifunctional proteins that can act both as cytokines 
and morphogens. TGF- 1 is the prototype of a subfamily containing 3 highly conserved 
isoforms (TGF- 1, TGF- 2, and TGF- 3). These three isoforms are secreted as latent 
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precursor molecules, which are usually complexed with latent TGF-  binding proteins, 
requiring activation into a mature form for receptor binding and subsequent activation of 
signal transduction pathways (Verrecchia and Mauviel, 2007, Keski-Oja et al. 2004). Each 
isoform has differential biological effects, with distinct tissue and developmental 
expression patterns. TGF- 1 is highly conserved between species. TGF- 1 is an 112 
amino acid (12.5 kDa) protein, but physiologically, the ligand exists as a 25 kDa disulfide-
linked homodimer. TGF- 1 has many roles and influences cellular function in many ways: 
cell proliferation, growth inhibition, differentiation, apoptosis, immunosuppression, 
angiogenesis, wound healing, extracellular matrix deposition, motility, and adhesion
(Ruscetti et al. 1998). TGF- 1 stimulates the growth of mesenchymal cells, while 
inhibiting the growth of epithelial cells and many cells of the immune system. The 
physiological effects of TGF- 1 are cell-context specific; depending on the type, state of 
differentiation, and growth conditions of the cell. TGF- 1 interacts with and exerts its 
effects through two high-affinity cell surface receptors, the type III TGF-  receptor 
(T RIII) and the type II TGF-  receptor (T RII). T RII ultimately complexes with the 
type I TGF-  receptor (T RI), which activates the intracellular smad transcription factors. 
TGF-  binds to the receptor-complex on the cell surface, a complex of two pairs of 
subunits known as receptor type I (T R-I, also known as ALK-5) and type II (T R-II). 
Type III receptor or betaglycan, a membrane-anchored proteoglycan, aids this process by 
capturing TGF-  for presentation to the signalling receptors I and II (Massagué and 
Gomis, 2006). Furthermore, TGF-  binds to the endothelial-specific T R-III-like receptor, 
endoglin, and to the type I TGF-  superfamily member ALK-1. In addition, TGF-  binds 
another small proteoglycan, decorin, an alpha-amyloid precursor protein and the serum 
glycoproteins fetoprotein and fetuin (Binkert et al. 1999). 
Virtually every cell displays at least one of the TGF-  binding receptors (T RIII and/or 
T RII) and responds in some manner to TGF- , which means that it is crucial that there is 
a strict regulation at the protein level (Massague et al. 1992). Uniquely among cytokines, 
TGF-  is predominantly secreted from cells as an inactive or latent complex that is unable 
to bind to its receptor (Pircher et al. 1986). TGF-  is synthesized as a 390 amino acid 
precursor and secreted as a latent complex that exists in one of two major forms: the small 
and large latent complexes. The small latent complex (~100 kDa) consists of the mature 
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TGF- 1 peptide at the carboxy-terminus covalently linked to latency-associated protein 
(LAP) at the amino-terminus. The large latent complex (~235-260 kDa) consists of the 
small latent complex and a latent TGF-  binding protein (LTBP), which is linked to the 
complex through a disulfide bond with the LAP (Miyazono et al. 1993). The LTBP 
appears to be important in the efficient secretion of TGF- . The exact mechanism by 
which the latent form is converted to the active form remains unknown. It is thought that 
activation occurs through proteolytic cleavage or alterations that lead to changes in the 
conformation of the latent complex. TGF- 1 may also be further modified through 
phosphorylation and/or glycosylation. Activation of TGF- 1 is also cell-context specific 
(Lawrence 2001). The TGF- 1 protein is highly conserved in mammals: it is identical in 
man, pig, and cow, and differs by only one amino acid in mice. In general, the structure, 
activation, and signaling of murine TGF-  receptors are similar to those encountered in 
human receptors (Ruscetti et al. 1998). 
Many factors are able to increase TGF- 1 transcription. In particular, TGF- 1 itself can 
induce TGF- 1 production in a positive-feedback loop. Importantly, mRNA levels of 
TGF- 1 are not an accurate indication of the protein production or protein activity, since 
the amount of active TGF- 1 is highly regulated and TGF- 1 can be activated without 
increasing protein synthesis. In addition, protein production can be increased, in the 
absence of transcription, through the binding of a regulatory protein to the 5'-untranslated 
region stem loop of TGF- 1 mRNA (Van der Velden and Thomas, 1999). Also, the 
activation of latent TGF- 1 can enhance TGF- -mediated effects and there are estimates 
suggesting that only 2% to 5% of the latent protein is activated (Flaumenhaft et al. 1993). 
Thus, the activation of TGF- 1 is highly restricted and localized compared to the broad 
distribution of the latent complex. The availability of active TGF-  is likely transient and 
probably restricted to the local environment (Ruscetti et al. 1998). Varying levels of TGF-
1 expression have been linked in many diseases. TGF- 1 is often up-regulated in a 
number of different types of cancer. At the subcellular level, TGF- 1 can be found in the 
extracellular matrix, on the cell surface, and within endocytic vesicles (Letterio and 
Roberts, 1998, Makinde et al. 2007, Penheiter et al. 2002).
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The TGF- 1 knockout mouse survives to birth, unlike the knockouts of the other two 
TGF-  isoforms. However, the TGF- 1 knockout animals die within 3 weeks with 
inflammatory cell infiltration in multiple organs and massive inflammation (Shull et al.
1992). TGF- 1 has also been shown to activate the p38, mitogen-activated protein kinases 
(MAPK), Jun N-terminal kinase (JNK), and ERK pathways, and Rho family members, 
although the exact mechanism is unknown (Nickl-Jockschat et al. 2007, Zhang et al. 2006, 
Derynck and Zhang, 2003). 
5.5.2. Transforming growth factor -  in asthma and allergy
TGF-  has a significant role in the regulation of the allergen-induced immune response. It 
participates in the development and regulation of allergic and asthmatic inflammation. It 
appears to attenuate the inflammatory response and to contribute to the airway remodeling 
associated development of fibrosis. 
TGF-  family proteins have multiple functions which in some cases can be conflicting - 
either stimulating or inhibiting - in affecting immune cell functions and in this way it has 
complex effects on the function and activity of immune cells (Meadows et al. 2006, Ito et
al. 2006, Smeltz et al. 2005). Most, if not all, mature cells produce TGF- , enhanced 
TGF-  expression occurs during tissue repair, bone remodelling, and inflammation (Wahl, 
1992).
Also blood platelets store high levels of TGF-  delivering it among inflammatory cells at 
the sites of tissue injury (Wahl, 1994). TGF-  activates cellular mitogen-activated protein 
kinase signaling pathways, which crosstalk with Smad signaling and regulate growth, 
survival and motility of cells (Leivonen and Kähäri, 2007). TGF-  activates elastin 
transcription, which is important for lung development and postnatal maturation as well as 
for repair following injury (Kuang et al. 2007). TGF- /Smad signaling mediates also the 
induction of ECM glycoproteins required for normal elastogenesis during lung injury and 
repair (Kuang et al. 2006). 
Increased activation of the TGF- -pathway has been observed in the skin and lung, 
especially during tissue injury and inflammation (Munger et al. 1999). Children with 
35
atopic dermatitis exhibit a significantly higher proportion of a low TGF- 1 cytokine 
producing allele compared to healthy controls (Arkwright et al. 2001).
As stated above, the reaction of epidermal LCs to haptens or metals is the initial step in 
allergic contact sensitivity. It has been proposed that one way to study the biological role 
of epidermal LC in allergic contact sensitivity, is to substitute the immature epidermal 
LCs with TGF-  -treated dendritic cells; this has been claimed to provide a good in vitro
model (Aiba et al. 2000). TGF-  contributes to the initiation step in the allergic contact 
sensitivity reaction.
It has been reported that TGF-  down-regulates TARC/CCL17 synthesis and in this way it 
can decrease the TARC-related inflammatory processes such as AD (Zheng et al. 2002).
TGF-  may decrease allergic inflammation by inhibiting IgE synthesis in IL-4-treated 
human B cells and by inhibiting the proliferation of mast cells. TGF-  has been shown to 
inhibit Th2 lymphocyte differentiation (Gorelik et al. 2000, Jutel et al. 2003). AHR and 
airway eosinophilia in murine asthma were reversed by T lymphocytes manipulated to 
overproduce TGF-  (Hansen et al. 2000). 
The earliest studies linking TGF-  to inflammation modulation showed enhance TGF
gene transcription and production in bronchoalveolar mononuclear cells (Deguchi and 
Kishimoto, 1991). Subsequently, TGF-  has been detected in the sputum of asthmatics 
(Adachi et al. 1996) and in the BAL fluid of asthmatics both basally and at 24 h following 
allergen challenge (Redington et al. 1997). It has been reported that TGF-  contributes to 
airway inflammation via macrophages (Prieto et al. 2000), neutrophils (Chu et al. 2000), 
and eosinophils (Ohno et al. 1996, Vignola et al. 1996). The increased levels of TGF-  in 
the BAL fluid of a murine model of asthma were found to correlate with airway 
hyperresponsiveness, airway inflammation, collagen deposition, subepithelial fibrosis, and 
IgE/IgG1 responses (Tanaka et al. 2001). The TGF-  secreted from CD4+ T cells has 
been shown to eliminate allergen-induced eosinophilia (Haneda et al. 1999). Also, CD4+ 
T cells genetically engineered to express TGF-  were shown to reverse allergen-induced 
hyperreactivity and airway inflammation in a murine model of asthma (Hansen et al.
2000).
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TGF-  is known to induce IL-11 production, which causes nodular mononuclear 
infiltrates, airway hyperresponsiveness, airway remodeling, subepithelial fibrosis, and 
airway obstruction (Zheng et al. 2001). In a murine model of asthma, TGF-  was shown 
to suppress Th2-cell induced airway hyperresponsiveness and airway inflammation 
(Hansen et al. 2000). TGF-  is a fibrokinetic cytokine that induces extra-cellular matrix 
production, such as collagen. Nomura et al. demonstrated in the asthmatic airway that 
TGF-  could stimulate eosinophils to synthesize collagen (Nomura et al. 2002). Collagen 
deposition in the epithelial basement membrane is a feature of airway remodeling, and 
accumulation of collagen contributes to basement membrane thickening. It was shown that 
plasmin-released TGF-  could induce airway smooth muscle cells, which synthesize 
collagen I in an autocrine manner, contributing to irreversible airway remodeling and 
fibrosis (Coutts et al. 2001). 
It has been suggested that the development of airway hyperresponsiveness and airway 
remodeling in asthmatic airways is regulated by the expression of Smad7, intracellular 
antagonist of TGF- , in bronchial epithelial cells. A decreased expression of Smad7 leads 
to an increased susceptibility of TGF  on bronchial epithelial cells, causing an increased 
basement membrane thickness, airway hyperresponsiveness and airway remodeling 
(Nakao et al. 2000, 2002). Increased expression of phosphorylated Smad2, the TGF-
signal transducer, was detected in bronchial biopsy specimens from asthmatics and the 
increased expression correlated with basement membrane thickness (Sagara et al. 2002). 
5.6 Smad proteins and TGF-  signaling pathways 
5.6.1 Smad proteins 
Smad proteins are a family of transcription factors that mediate TGF-  signals.The term 
Smad originates from the founding members of this family, the Drosophila protein MAD 
(Mothers Against Decapentaplegic) and the Caenorhabditis elegans protein SMA (Small 
body size) (Massagué 2000). In general, Smad proteins are about 500 amino acids in 
length and consist of two globular domains coupled by a linker region (Shi and Massagué, 
2003). Smad transcription factor mediates TGF-  signals into the cell nucleus. The action 
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of the components that transport SMADs to the specific target genes induces a certain 
target gene or many potential genes to respond to the SMAD (Massagué 2000). 
On the basis of structural and functional characteristics, the Smad family can be divided 
into three groups consisting of eight distinct Smad proteins: the receptor regulated Smad 
(R-Smad, Smad1, 2, 3, 5, and 8), the Co-mediator Smad (Co-Smad, Smad4), and the 
inhibitory Smad (I-Smad, Smad6, 7). R-Smads (Smad1, 2, 3, 5, and 8) can be directly 
phosphorylated and activated by the type I receptor kinases and form heteromeric 
complexes with the Co-Smad, Smad4. The activated Smad complexes translocate into the 
nucleus and, via an interaction with other nuclear cofactors, they regulate the transcription 
of target genes. Smad1, Smad5 and Smad8 mediate signals downstream of bone 
morphogenetic proteins (BMP), whereas Smad2 and Smad3 mediate signals triggered by 
TGF- s and activins (Leivonen and Kähäri, 2007). The I-Smad (Smad6 and 7) compete 
with R-Smads for receptor binding or for Co-Smad interaction and they are also involved 
in targeting the receptors for degradation (Shi and Massagué, 2003). Smad7 is a general 
inhibitory Smad capable of inhibiting signals triggered by TGF- s, activins and BMPs, 
whereas Smad6 inhibits only signals triggered by BMPs (Leivonen and Kähäri, 2007). 
Table 3 The mammalian Smad family members can be divided into three groups 
according to their function. R-Smad, receptor regulated Smad; Co-Smad, common-
mediator Smad; I-Smad, inhibitory Smad; BMP, bone morphogenetic protein. 
     
R-Smads (Smad1, 2, 3, 5, 8) Receptor-activated Smads mediating 
signals triggered by TGF- s and activins 
(Smad2, 3) or BMPs (Smad1, 5, 8). 
Co-Smad (Smad4) Forms heteromerix complexes with R-
Smads. 
I-Smads (Smad6, 7) Inhibitory function by competing with R-
Smads for receptor or Co-Smad interaction 
or by directing TGF-  receptors for 
degradation.
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5.6.2 Smad-dependent pathways in TGF-  signalling 
TGF- /Smad -signalling is a linear signalling pathway; TGF-  induces signalling 
responses from the type II to the type I receptor kinase evoking Smad activation causing 
ligand-induced transcription. TGF-  binds to membrane receptors that have a cytoplasmic 
serine/threonine kinase domain. Binding of the ligand leads to the assembly of a receptor 
complex that phosphorylates proteins of the SMAD family. Phosphorylation causes the 
movement of SMADs into the nucleus where there is the formation of the complexes that 
directly control gene expression (Massagué 2000). Each ligand of the TGF  family binds 
to specific pairs of receptor serine/threonine kinases, which belong to groups type I (T R-
I, ALK5) and type II (T R-II) receptors. Most mammalian cells express different 
members of this receptor family, some of which may be shared by different TGF-  ligands 
(Massagué 2000). The ligand binding causes two type I and two type II receptors to 
dimerize. Receptor II is known to have one function; to activate receptor I by 
phosphorylation of the regulatory region in the TGF-  receptor (Wrana et al. 1994). 
Subsequently, the type I receptor phosphorylates SMAD proteins and in this way increases 
their affinity for Co-Smads. The resulting Smad-complex moves into the nucleus and is 
able to associate with transcriptional co-activators or co-repressors. In the absence of 
phosphorylation, Smads are transcriptionally inert (Massagué and Gomis, 2006). The 
Smads have some affinity for DNA, however, effective binding to particular gene 
regulatory sites is potentiated by specific DNA-binding cofactors (Massagué 2000). R-
Smads that have moved into the nucleus may return to the cytoplasm, though their 
ubiquitylation- and proteasome-dependent degradation in the nucleus is one way to 
terminate TGF-  responses (Lo and Massagué, 1999). Activated Smad proteins are 
recognized by protein phosphatases and ubiquitin ligases that terminate the signaling 
process. It has been reported that under conditions of TGF-  stimulation, Smads 
constantly undergo cycles of receptor-mediated phosphorylation and phosphatase-
mediated dephosphorylation, moving in and out of the nucleus (Inman et al. 2002). 
Smad signaling is essential for most, but not all, TGF-  gene responses. TGF-  activates 
other signalling cascades including the mitogen-activated protein kinase (MAPK) 
pathway. In addition, a variety of mediators such as ERK, Jun N-terminal kinase (JNK), 
p38 MAPK kinase, phosphatidylinositol-3-kinases (PI3Ks), protein phosphatase 2A 
(PP2A phosphatases) and Rho family members can be activated. Some of these pathways 
regulate Smad activation, but it is also possible that they can induce responses unrelated to 
transcription (Derynck and Zhang, 2003). 
5.6.3 Smad3 deficiency in mice 
Smad3 plays a key role in TGF- /Smad-mediated transcriptional regulation. Smad3 has 
been indicated to be a critical effector in TGF- -mediated cellular responses and the 
modulation of the activity and the function of the immune system (Datto et al. 1999). 
Phosphorylated Smad3 forms a complex with Smad4, together they are translocated into 
the cell nucleus to regulate the transcription of target genes (Letterio and Roberts, 1997). 
Adult Smad3-deficient mice exhibit impaired mucosal immunity and diminished T cell 
responsiveness to TGF- , as well as a lower rate of bone formation and osteopenia 
through dysregulation of osteoblast differentiation and apoptosis (Yang et al. 1999, Borton 
et al. 2001). Smad3-null mice also display an increased rate of wound healing and an 
impaired local inflammatory response (Ashcroft et al. 1999). Mice lacking Smad3 are 
protected against various cutaneous injuries (Flanders et al. 2002, Flanders et al. 2003, 
Saika et al. 2004). It has been reported that Smad3-deficiency can increase the incidence 
of metastatic colorectal tumors (Zhu et al. 1998). 
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Figure 3  TGF- /Smad signalling pathway. 1) Ligand induced receptor activation, 2) R-Smads 
 are phosphorylated, 3) R-Smads and Co-Smads form heteromeric complexes and 4) 
 translocate into the nucleus. 5) Smads control the expression of target genes in a cell 
 type specific manner.6) I-Smads are capable of inhibiting the phosphorylation of R-
 Smads. I-Smads compete with R-Smads for receptor or Co-Smad interaction. They 
 also direct TGF-  receptors to degradation. R-Smad = receptor-activated Smad, Co-
 Smad = common-partner Smad, I-Smad = inhibitory Smad, T R-I = TGF-  type I 
 receptor, T R-II = TGF-  type II receptor. 
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6. AIMS OF THE STUDY 
This thesis concentrates on studying the role of a specific transcription factor in TGF-  -
signalling pathway in allergic diseases. The role of TGF- -Smad3 -signalling in the 
immunoregulation and pathophysiology of allergic disorders is unknown. In this thesis, 
the effects of Smad3 deficiency have been studied using different animal models in 
allergic diseases and Smad3 knockout mice. 
The specific aims of this study were: 
1. To investigate the mechanism in inflammation caused by the defect in TGF-  -Smad3 -
signalling in an experimental model of atopic dermatitis (I). 
2. To evaluate the role of TGF-  -Smad3 -signalling in the regulation of lung functions in 
the healthy situation as well as in the disease state using a mouse model of asthma (II). 
3. To determine the immunological and histological changes caused by contact allergen 
and the significance of TGF-  -Smad3 -signalling in a mouse model of contact allergy 
(III).
4. To investigate the role of TGF-  -Smad3 -signalling and immunological changes after 
exposure to respiratory allergen in an experimental model of contact allergy (IV). 
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7. MATERIALS AND METHODS 
7.1 Smad3 knock-out mice 
Smad3ex8/ex8 knock-out mice (Smad3-/-) were provided by Dr. Chuxia Deng (NIH, 
Bethesda, MD, USA) and were further bred in the facilities of Finnish Institute of 
Occupational Health. Smad3-/- mice, seven- to 11-weeks of age were used in the 
experiments. Age and sex matched wild type (WT) offspring were used as littermate 
controls. All mice were housed in pathogen-free facilities. All animal experiments were 
approved by Social and Health Services of Finland, Provincial Office of Southern Finland 
(I - IV). 
7.1.1 Breeding and genotyping (I - IV) 
Heterozygous Smad3-/- mice were breeded and the resulting progeny were genotyped to 
identify Smad3-/- and WT mice: A short piece of tail, about 0.5 cm long, was clipped 
from each mouse to extract DNA. The tail was digested in the presence of protease K (100 
g/ml) in a buffer consisting of 10 mM Tris (pH 8.0), 100 mM NaCl and 1 mM EDTA at 
55 °C overnight. After centrifugation for 5 min at 13 000 rpm, the supernatant was 
collected and boiled at 100 °C for 20 min. The resulting solution (5 l per 25 l reaction 
volume) was used for genotyping by the standard PCR method using mouse primer pairs 
located in exons 6 and 9 revealing a fragment of 284 bp in Smad3ex8/ex8, and 431 bp in WT 
mice. To detect the wild type (431 bp fragment) the primer pair (5-
CCACTTCATTGCCATATGCCCTG-3) and (5-CCCGAACAGTTGGATTCACACA-3) 
was used and to detect the mutant Smad3 (284 bp fragment) the primer pair (5-
CCACTTCATTGCCATATGCCCTG-3) and (5-CCAGACTGCCTTGGGAAAAGC-3) 
was used. The PCR was performed in a Eppendorf Mastercycler gradient thermal cycler 
(Perkin-Elmer Corporation, Foster City, CA, USA) using the following cycling 
parameters:  1) 95 °C, 3 min; 2) 94 °C, 45 seconds; 60 °C, 45 seconds; 72 °C, 1 min; 
repeat for 32 cycles; 3) 72 °C, 10 min; 4) store at 4 °C. A 284 base pairs (bp) DNA band, 
formed by direct splicing from exon 6 to exon 9 (Yang et al. 1999) and a 431 bp DNA 
band, were visualized in a 1.5 % agarose gel stained with ethidium bromide. 
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7.2 Murine models of allergic diseases 
   
7.2.1  Atopic dermatitis (I) 
Sensitization  
Epicutaneous treatment and sensitization of mice were performed as described previously 
(Spergel et al, 1998). Inhalation of Isofluran (Abbott Laboratories, Abbott Park, IL) was 
used to anaesthetize the mice. The skin on the back of the mice was shaved with an 
electric razor and the shaved area was tape-stripped four times by transparent adhesive 
tape (Tegaderm, 3M Health Care, St Paul, MN) to remove hair and to introduce a 
standardized skin injury in stratum corneum to mimic scratching, a symptom of atopic 
eczema. A sterile gauze patch (1x1 cm2) moisturized with 100 l of 0.1% OVA in saline 
(OVA group) or 100 l of 0.9% saline (saline group) was placed on the back skin of the 
mice being attached with Tegaderm adhesive tape.  
The patches were kept in place for 1 week and then removed. Two weeks later, an 
identical patch was applied to the same skin site. The total experiment contained three 1-
wk exposures with 2-wk intervals between each exposure. After the last sensitization 
week, on sacrifice of the mice, blood and skin biopsies were collected for further analysis. 
The experiment was performed three times. 
7.2.2 Allergic contact reactions 
Induction of contact hypersensitivity (III, IV) 
Epicutaneous treatment and sensitization of mice was performed according to the method 
described by Lauerma et al (Lauerma et al. 1997). Mice were lightly anesthetized with 
inhalation of Isofluran (Abbott Laboratories, Abbott Park, IL) and sensitized on shaved (4 
cm2) and tape-stripped (three times) back skin with 50 l oxazolone (10 mg/ml) or 100 l
trimellitic anhydride (TMA) (500 mg/ml) in a 4:1 acetone:olive solution on day 0. A 
control group was treated similarly with only vehicle. 
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Elicitation (III, IV) 
On day 7, the mice were shaved on the back and 50 l oxazolone (1 mg/ml) or TMA (250 
mg/ml) in a 4:1 acetone:olive solution was applied onto the skin. Before allergen 
application on the back of both ears, the thickness of ears was measured with a micrometer 
to obtain the baseline level. After the measurement, oxazolone (50 l, 1 mg/ml) or TMA 
(50 l, 250 mg/ml) was applied topically on each ear. In the experiment with oxazolone, 
the thickness of ear was measured 24 and 48 hours after allergen application. The mice 
were sacrificed after the last sensitization and ear draining lymph nodes, ears and skin 
biopsies were collected for further analysis.  
Second elicitation (IV) 
On day 14, the mice were shaved on the back (no tape stripping) and 50 l TMA (250 
mg/ml) was reapplied on the skin in a 4:1 acetone:olive solution. The thickness of ears 
was measured with a micrometer before TMA application for baseline level. After the 
measurement, TMA (50 l, 250 mg/ml) was applied on the back of both ears topically. 
The thickness of ear was measured 1, 2, 4, 24 and 48 hours after allergen application. The 
mice were sacrificed after the last timepoint. Ear draining lymph nodes, ears and skin 
biopsies were collected for further analysis.  
Sample collection and preparation (III, IV) 
Skin biopsies from treated skin areas and one ear draining lymph node were used for RNA 
isolation. The size of the other ear draining lymph node was measured and used for the 
proliferation test. The ears were weighed and measured with electronic digital micrometer 
at 0 h, 24 h, and 48 h after oxazolone treatment and at 0 h, 1 h, 2 h, 4 h, 24 h, and 48 h 
after the TMA treatment. 
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7.2.3  Asthma (II) 
Induction of Allergic Airway Disease 
The short-term asthma model was used in this thesis. Mice were sensitized 
intraperitoneally on day 0 and 10 with ovalbumin in alum or PBS emulsified in alum. On 
days 20-22, the mice were challenged with aerosolized 1% OVA, for 20 minutes per day. 
Airway responsiveness was measured 24 hours after the last airway challenge and 
specimens were collected.
Challenge of eight mice per group was performed in three separate experiments. In 
addition to the treated mice, the samples from eight naive Smad3-/- mice and eight, age 
and sex matched, naive WT mice were collected. 
7.3 Histology and immunohistochemistry 
7.3.1 Skin 
Sample collection and skin preparations (I, III, IV) 
The collected blood was used for antibody analysis. Skin biopsies from treated skin areas 
were used for RNA isolation, histology and immunohistochemical examination. For 
histology, the skin was fixed in 10% formalin, embedded in paraffin wax, sectioned 5 um 
thick, and stained with H&E and with Periodic Acid Schiff (PAS) stain and examined 
under light microscopy. For immunohistochemical staining, the skin was embedded into 
Tissue-Tek OCT compound (Sakura, AA Zoeterwoude, The Netherlands) and quick 
frozen. The skin samples were cut into 5 um sections and stained immunohistochemically 
with monoclonal antibodies against CD11c, CD3, CD4 or CD8 (BD, Pharmingen, San 
Jose, CA) using the ChemMate (DakoCytomation, Glostrup, Denmark) staining kit.
7.3.2 Lung 
Cell recovery and histology of lungs (II) 
The bronchoalveolar lavage was stained with May-Grünwald-Giemsa (MGG) stain and 
the cells were counted. The remaining cells were fixed in ethanol (1:2). One part of the left 
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lung was removed for RNA isolation. The right lung was fixed in 10% formalin, 
embedded in paraffin wax, sectioned 5 um thick, and stained with H&E and Periodic Acid 
Schiff (PAS) and examined under light microscopy. 
7.4  Molecular biology (I - IV) 
RNA isolation and cDNA synthesis 
Skin biopsies of the sacrificed mice, obtained at 48 hours after the second allergen 
exposure, were snap frozen on dry ice and kept at -80 C until homogenized with an Ultra-
Turrax T8 (IKA Labortechnik) in TRIzol (Invitrogen Life Technologies). RNA extraction 
was performed according to TRIzol instructions, followed by DNAseI (RNase-free; 
Invitrogen Life Technologies) treatment to remove contaminating genomic DNA, and 
further extraction with phenol-chloroform-isoamylalcohol (25:24:1). MultiScribe reverse 
transcriptase and random hexameres (Applied Biosystems) were used to reverse transcribe 
one microgram of extracted RNA into cDNA. 
Real-time quantitative PCR 
Total RNA from skin or lung was extracted and transcribed into cDNA. Real-time 
quantitative PCR was performed with an AbiPrism 7700 Sequence Detector System 
(Applied Biosystems, Foster City, CA). The PCR primers and probes were TNF- , IL-6, 
IL-1 , IL-4, IFN- , IL-13, IL-10, GATA-3, STAT-4, Foxp3, IL-17, TGF- 1, CXCR3, 
CCR3, CCR5, CXCL10/IP-10, CCL3/MIP-1 , CXCL5/LIX, CXCL9/MIG, 
CCL24/eotaxin-2   (Applied Biosystems) and endogeneous 18S rRNA was used as the 
housekeeping gene and the target gene expression was expressed as relative quantities. 
7.5 Immunochemistry (I, II, IV) 
ELISA
OVA-specific IgE, IgG1 and IgG2a serum levels were measured by ELISA method (I, II). 
Ninety-six-well microtiter plates (Nunc, Rochester, NY) were coated with 100 g/ml 
OVA in 0.05 M NaHCO3 (pH 9.6) at 4°C overnight. PBS-Tween 20 (0.05%) was used for 
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washing and the plates were blocked with 3% BSA in PBS for 2 hours at 20°C and 
washed again. One hundred microliters of diluted sera (1/10, 1/20, 1/40, 1/80) in 1% BSA-
PBS were incubated overnight at 4°C. After washing, 2 g of biotin-conjugated rat anti-
mouse IgE mAb in 1 ml of 1% BSA-PBS was incubated for 2 h at 20°C and washed again. 
Streptavidin-HRP (BD, Pharmingen, San Jose, CA) 1/4000 in 1% BSA was added and 
incubated for 30 min at 20°C and washed. After addition of peroxidase substrate 
(Kirkegaard & Perry Laboratories, Gaithersburg, MD), the absorbance was read at 405 nm 
with ELISA reader (Multiskan MS, Labsystems, Vantaa, Finland). OVA-specific IgG2a
was measured by using the same method described. The plates were coated with 2 g/ml 
OVA in 0.05 M NaHCO3 (pH 9.6). Serial dilutions of sera for IgG2a (1/60, 1/180, 1/540, 
1/1620) were used. Bound IgG2a was detected with biotin-conjugated rat anti-mouse IgG2a
mAb (BD, Pharmingen, San Jose, CA). 
 TMA-specific IgE and IgG2a serum levels were measured by ELISA method (IV). First, 
TMA-mouse serum albumin (MSA) -conjugate was prepared; TMA in acetone (117 
mg/ml) was added (10 μl/10 ml) to the cooled solution of MSA in 0.05 M NaHCO3 (500 
μg/ml, pH 9.0). The mixture was allowed to react on ice for 60 min. The conjugates were 
checked by high-performance liquid chromatography (HPLC) and purified from unreacted 
components and acetone using Centricon column equilibrated with 50 mM carbonate 
buffer at pH 9.6. The TMA-MSA conjugate was used for coating microtiter plates (Nunc, 
Rochester, NY) with 10 g/ml TMA-MSA conjugate in 0.05 M NaHCO3 (pH 9.6) at 4°C 
overnight. The plates were washed with PBS-Tween 20 (0.05%) and blocked with 3% 
BSA in PBS for 2 hours at 20°C and washed again. One hundred microliters of diluted 
sera in 1% BSA-PBS were incubated at 4°C overnight. After washing, 2 g of biotin-
conjugated rat anti-mouse IgE mAb in 1 ml of 1% BSA-PBS was incubated for 2 h at 
20°C and washed again. Streptavidin-HRP (BD, Pharmingen, San Jose, CA) 1/4000 in 1% 
BSA was added and incubated for 30 min at 20°C and washed. Peroxidase substrate 
(Kirkegaard & Perry Laboratories, Gaithersburg, MD) was added and absorbance read at 
405 nm with ELISA reader (Multiskan MS, Labsystems, Vantaa, Finland). TMA-specific 
IgG2a was measured by using the same method described above. Serial dilutions of sera 
for IgG2a were used and bound IgG2a was detected with biotin-conjugated rat anti-mouse 
IgG2a mAb (BD, Pharmingen, San Jose, CA). 
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Measurement of cytokines by LuminexTM (II) 
IL-13, IL-5 and IL-4 cytokines of BAL-samples were measured on a LuminexTM (Bio-Plex 
200 System) using the Bio-Rad mouse cytokine kit (Bio-Plex cytokine assay) following 
the manufacturer's instructions. A minimum of 100 beads per analyte was used for the data 
collection using Bio-Plex Manager Software (Bio-Rad Laboratories, Inc, Hercules, CA).
7.6  Cell culture (III, IV) 
Proliferation test 
Ear draining lymph node cells (105 cells per well suspended in 200 ul RPMI-1640) were 
incubated in 37 °C / 5 % CO2. Lymph node cells were pulsed for 36 hours with 1 Ci [3H]
thymidine per well (Amersham Biosciences Europe, Freiburg, Germany). Incorporated 
radioactivity was measured in a liquid scintillation counter (Trilux 1450 Microbeta, 
Wallac, Turku, Finland). Results were expressed as mean counts per minute (cpm) of 
triplicate wells +/- SEM. 
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8. RESULTS 
8.1. Cutaneous responses in the model of atopic dermatitis (I) 
Dermal thickness in OVA -sensitized skin sites of Smad3-/- mice was significantly 
reduced compared to their WT littermates. The epicutaneous OVA sensitization increased 
significantly the thickness of dermis and epidermis of WT mice compared to saline treated 
controls. Similarly, the thickness of the epidermis was enhanced in the OVA-sensitized 
skin of Smad3-/- mice although the difference was not statistically significant.
In the OVA-sensitized skin, the number of mast cells was significantly increased in the 
Smad3-/- mice compared to WT mice. The mast cell numbers remained at a low level in 
OVA-sensitized WT mice. 
Skin infiltrating eosinophils were significantly increased in OVA-sensitized WT mice 
compared to saline sensitized controls. The numbers of eosinophils were elevated after 
OVA sensitization also in Smad3-/- mice compared to their saline treated controls though 
this was not statistically significant. CD11+ cells were equally elevated in the skin of 
Smad3-/- mice and their WT littermates after OVA sensitization. In addition, increased 
numbers of CD3+, CD4+ and CD8+ cells were observed in the skin of Smad3-/- mice and 
WT mice after epicutaneous OVA sensitization. However, no significant differences in 
lymphocyte numbers between the Smad3-/- mice and WT mice were detected. 
The OVA sensitized skin of Smad3-/- mice expresses drastically lower amounts of  IL-6 
and IL-1  mRNA compared to their WT littermates. There were no significant differences 
in the expression of proinflammatory cytokines IL-6, IL-1  and TNF-  mRNA between 
OVA sensitized and saline sensitized skin in Smad3-/- mice. The mRNA expression of 
TNF- , IL-6 and IL-1  was significantly increased in OVA-sensitized skin sites of WT 
mice compared to saline treated controls.  
The expression levels of a major Th2 cytokine IL-4 and Th1 cytokine IFN-  were 
significantly higher in the skin of OVA-sensitized mice compared to saline treated 
controls, but no significant difference between Smad3-/- and WT mice was observed.  
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8.2. Antibody responses in the model of atopic dermatitis (I) 
The OVA-specific IgE response was enhanced significantly in Smad3-/- mice after OVA 
sensitization compared to their WT littermates. In addition, the levels of OVA-specific 
IgG2a were induced after OVA sensitization in both mice groups but no significant 
differences in antibody levels between WT and Smad3-/- mice were detected. 
8.3. Cellular infiltration in the lung in the mouse model of asthma (II) 
After the last saline or OVA challenge, the mice were killed and the lungs were removed. 
One part of the lung was stained with hematoxylin and eosin (H&E), and another part with 
periodic acid-Schiff's reagent (PAS) for PAS -positive cell counting. The numbers of PAS 
-positive cells were increased in the Smad3-/- animals sensitized with OVA compared to 
WT mice. Moderate airway inflammation with peribronchiolar and perivascular infiltrates 
consisting of lymphocytes and eosinophils was seen in the lung sections from Smad3-/- 
and WT mice sensitized with OVA. The infiltrate of Smad3-/- mice, but not WT mice, 
consisted of neutrophils. Alveolar macrophage aggregates were detected in Smad3-/- 
mice, but not in WT mice. In addition, the cell counts of saline sensitized mice were 
higher in Smad3 -/- mice compared to those of WT mice. The lung histology of naive, 
unsensitized Smad3-/- mice (3/8), displayed small patch areas with perivascular 
inflammation and macrophages.
The percentage of lymphocytes was significantly increased in the BAL of Smad3-/- mice 
compared to WT mice. The amount of eosinophils was increased in the BAL fluid of all 
OVA-sensitized mice. Neutrophil and macrophage counts in the BAL fluid of Smad3-/- 
saline treated mice were significantly increased compared to WT saline group.   
8.4. Antibody response in the mouse model of asthma (II) 
One indication of allergic asthma is the production of allergen specific IgE. Blood was 
collected after the mice sacrifice and OVA-specific IgE, IgG1 and IgG2a in the serum were 
measured by ELISA. OVA-specific IgE levels were increased in Smad3-/- and WT mice 
sensitized with OVA. Moreover, increased OVA-specific IgG1 and IgG2a levels in OVA 
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sensitized Smad3-/- and WT mice were observed, IgG1 level being slightly higher in WT 
animals. 
8.5. Airway hyperreactivity (II) 
Whole-body-plethysmography was used to test mouse airway hyperreactivity (AHR) in 
response to methacholine after the last OVA or saline sensitization. Smad3-/- OVA-
sensitized mice exhibited difficulties in breathing already at lower methacholine 
concentrations. All three separate experiments displayed a trend in which the PenH pdc 
value was higher in OVA-sensitized Smad3-/- mice compared to OVA-sensitized WT 
mice. 
8.6 Cytokine and chemokine expression in the lung (II) 
IL-13 and IL-5 mRNA levels were significantly increased in OVA-sensitized WT mice 
compared to OVA-sensitized Smad3-/- mice. The IL-6 level was slightly higher after 
OVA sensitization in WT mice compared to Smad3-/- mice. The mRNA level of GATA-3 
was significantly higher in the lung of naive, unsensitized Smad3-/- mice compared to that 
of WT mice. Interestingly, naive Smad3-/- expressed also higher levels of TGF- 1 mRNA 
compared to naive WT mice. GATA-3 expression was increased also in OVA sensitized 
WT mice, but not in Smad3-/- mice. The levels of IL-4, IL-10, CXCR3 and CCR4 mRNA 
were significantly higher in OVA-sensitized animals compared to saline treated animals, 
but no significant difference between Smad3-/- and WT mice was detected. The same 
observation was detected in the level of CCR1 mRNA, but the difference was not 
statistically significant. The differences in mRNA levels of CXCL2 were small between 
groups. OVA sensitization seemed to increase the mRNA expression of macrophage 
inflammatory protein 1  (MIP-1 ) in the lung. In addition, the protein levels of IL-13, IL-
4 and IL-5 in BAL-fluid were examined. IL-13 and IL-5 levels tended to be deceased in 
OVA-sensitized Smad3-/- mice when compared to WT mice but the differences were not 
significant. IL-4 level were higher in Smad3-/- mice but again the results were not 
significant. However, the levels of IL-4 protein were significantly elevated in the BAL of 
saline treated Smad3-/- mice compared to WT mice. Finally, the basal levels of all Th2 
cytokines IL-13, IL-4 and IL-5 were significantly increased in naive Smad3-/- mice as 
compared to naive WT mice. 
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8.7 Size of ear draining lymph nodes and cell proliferation in allergic contact 
reactions (III, IV) 
A five fold proliferation of lymph node cells was detected in oxazolone treated mice 
compared to the control mice. No difference between Smad3-/- and WT mice was 
detected. The size of ear draining lymph nodes was also significantly increased 
(approximately four fold) in oxazolone sensitized mice compared to the control groups. 
However, a significant difference in both the proliferation of ear draining lymph node cells 
and in the size of ear draining lymph node was detected in TMA treated Smad3-/- mice 
compared to WT mice. The proliferation of lymph node cells was doubled in TMA treated 
Smad3-/- mice compared to WT mice and the increased cell count reflected also the 
doubled size of ear draining lymph node of the Smad3-/- mice. There was a five fold 
elevation in the proliferation of lymph node cells in TMA treated WT mice compared to 
the control mice and the size of ear draining lymph node was approximately three fold 
higher in the TMA treated in comparison with untreated WT mice. 
8.8 Ear swelling responses in allergic contact reactions (III, IV) 
In the time-course study, the ear thickness was measured 0, 24, and 48 h after the 
oxazolone challenge. The ear thickness increased with time, but there were no significant 
differences between Smad3-/- and WT mice. The ear weight was significantly increased in 
sensitized mice compared to the control animals, but there was statistically no significant 
difference between WT and Smad3-/- mice. After TMA application, the ear thickness was 
measured at time points of 0, 1, 2, 4, 24, and 48 h. The ear thickness increased with time, 
but there was no significant difference between Smad3-/- and WT mice. The ear weight 
was slightly increased in sensitized mice compared to the control animals, but there were 
no significant differences between WT and Smad3-/- mice. 
8.9 Cell response in allergic contact reactions (III, IV) 
A significant increase in the infiltration of neutrophils was detected in oxazolone treated 
Smad3-/- mice compared to WT mice. The amount of eosinophils, CD4+ cells and the 
thickness of epidermis was increased upon oxazolone application but no significant 
difference was detected between Smad3-/- and WT mice. The numbers of skin infiltrating 
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eosinophils, lymphocytes, and neutrophils were elevated in TMA treated mice. The 
thickness of epidermis was significantly increased in TMA treated mice and also the 
thickness of dermis was increased after TMA treatment, this being statistically significant 
in Smad3-/- mice. 
8.10 Chemokine and cytokine skin responses in allergic contact reactions (III, IV) 
mRNA expressions of CCL3/MIP-1  and CCL24/eotaxin-2 were dramatically increased 
in the oxazolone treated skin of Smad3-/- mice compared to WT mice. No evidence of 
mRNA for CXCL5/LIX was observed in the skin of oxazolone WT mice. The level of 
CCR3 was significantly increased in oxazolone treated Smad3-/- mice compared to WT 
mice. The expressions of CCR5, CXCL9/Mig, CXCL10/IP-10 were increased 
significantly on oxazolone application compared to vehicle control, but no significant 
differences between Smad3-/- and WT mice were detected. 
The levels of proinflammatory cytokines IL-6, IL-1 , and TNF-  and also TGF-  were 
significantly increased in oxazolone challenged Smad3-/- mice compared to WT mice. 
Also the expression of a major Th2 cytokine IL-4 was significantly increased in Smad3-/- 
mice compared to WT mice. In contrast, no significant differences in the mRNA 
expression of IFN-  and IL-10 were detected between Smad3-/- and WT mice. T-
regulatory cell associated Foxp3 mRNA was significantly increased in oxazolone 
challenged Smad3-/- mice compared to WT mice. 
Also in the skin of TMA sensitized Smad3-/- mice, the expressions of the 
proinflammatory cytokines IL-6, IL-1  and TNF-  mRNA were increased compared to 
WT mice. The mRNA for IL-4 was increased in the skin of TMA sensitized Smad3-/- 
compared to WT littermates, but the difference was not significant. The levels of skin 
mRNA for IFN-  and IL-17 were significantly increased in TMA treated Smad3-/- mice 
compared to WT mice. Also the neutrophil attracting chemokines CCL3/MIP-1  and 
CXCL5/LIX were significantly increased in TMA treated Smad3-/- mice skin compared to 
WT mice. 
Th1 chemokine response was enhanced in TMA treated mice. CXCL10/IP10 and 
CXCL9/MIG, Th1 related chemokines, were significantly increased at the mRNA level in 
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TMA treated mice compared to the control mice. In addition, the mRNA expression of 
Th1 related chemokine receptor, CCR5, was increased both in WT and Smad3-/- mice, but 
significantly only in Smad3-/- mice. The Th2 associated chemokine receptor CCR3 was 
increased upon TMA treatment in WT and Smad3-/- mice, but this was not statistically 
significant.
8.11 Antibodies after TMA treatment in allergic contact reactions (IV) 
TMA-specific IgE levels were increased both in Smad3-/- and WT mice sensitized with 
TMA, but there were no significant differences in antibody levels between WT and 
Smad3-/- mice. In addition, the levels of TMA-specific IgG2a were induced after TMA 
sensitization in both mice groups, however, the levels were significantly decreased in 
Smad3-/- mice compared to their WT littermates.  
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9. DISCUSSION 
The role of TGF- -Smad3 -signalling in the immunoregulation and pathophysiology of 
allergic disorders is still poorly understood. Since TGF-  knock out mice are lethal at 
early age, using Smad3 knock out mouse in allergy research makes it possible to 
investigate the significance and role of TGF-  in allergic diseases. Because the role of 
Smad3 transcription factor has been studied in other diseases, it is possible to utilize this 
knowledge also in allergy research. The use of murine models either as germline or as 
tissue specific transgenic mice gives valuable immunological tools to investigate the 
significance of selected transcription factors or cytokines. Tissue specific transgenic lines 
have been generated into the Clara cell or CD2 promoter directing tissue- and immune 
cells specific expression of the gene of interest. DNA microinjection and stem cell 
transfer, as well as the on/off systems like Cre-lox models help to understand the role of 
selected genes in various steps of disease pathogenesis. In addition, transgenic models 
provide information and models for the validation of potential medication, for the 
development of more efficient and functional compounds as well as preclinical approval 
of therapy for allergic disease. In this thesis, the various murine models of allergic 
diseases were used with Smad3-/- mice enabling the investigation of the central TGF-
signalling pathway. 
9.1 TGF-  -signaling through Smad3 in the mouse model of atopic dermatitis 
Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory 
response (Ashcroft et al. 1999). It was anticipated in this thesis, based on the wound repair 
studies, that a defect in TGF-  -Smad3 -signalling would cause milder skin injury and 
inflammatory response in the experimental model of AD. Indeed, epicutaneous exposure 
to OVA in the skin of Smad3-/- mice resulted in significantly reduced dermal thickening 
and strongly decreased expression of proinflammatory cytokines IL-6 and IL-1  mRNA. 
However, dermal mast cells and OVA-specific IgE levels were significantly increased in 
Smad3-/- mice after OVA-sensitization. 
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Skin thickening, which may be caused by increased collagen deposits, is a characteristic 
feature of human AD. The pathology of many skin diseases is related to the regulation of 
the synthesis of extracellular matrix (ECM) molecules. The balance in the synthesis and 
breakdown of connective tissue is tightly controlled by the release of mediators, including 
TGF- , from inflammatory cells or connective tissue cells which can influence collagen 
and matrix metalloproteinase (MMP) production in both paracrine and autocrine fashions 
(Eckes et al. 2000). Disorders in this system cause wound healing defects or the 
development of fibrosis. Fibrosis is a normal consequence of chronic inflammation and 
tissue injury with excessive cell accumulation, skin thickening and deposition of ECM 
proteins. Many studies show the involvement of Smad3-TGF-  -signalling in the collagen 
transcription and in the mechanisms of fibrosis (Chen et al. 1999; Verrecchia et al. 2000). 
Type I collagen, the major component of ECM is composed of two 1 chains and one 2
chain which are the products of two genes, COL1A1 and COL1A2. After translation, the 
pro- 1 and pro- 2 polypeptides chains enter into the endoplasmic reticulum where 
specific proline and lysine residues are hydroxylated to form hydroxyproline and 
hydroxylysine. Thereby pro-  chains combine with other chains by hydrogen bonds and 
form the triple helix procollagen structure. After this procollagens are secreted through the 
Golgi apparatus in the extracellular space, where the N-terminal and C-terminal 
propeptides are cleaved by specific proteases. The mature processed collagen molecules 
aggregates to form larger collagens. Abnormalities in any step of type I collagen 
production may result in abnormally elevated synthesis of type I collagen which may 
cause tissue fibrosis (Verrecchia and Mauviel, 2007). Since Smad3 transmits TGF-
signals from the receptor to the procollagen gene in human fibroblasts (Chen et al. 1999), 
it might be that Smad3 regulates collagen production in the murine model of AD used in 
this thesis. Decreased secretion of collagen in Smad3-/- mice may result in reduced dermal 
thickness after epicutaneous OVA sensitization.  
The proinflammatory cytokines TNF, IL-1 and IL-6 are known to participate in the 
pathogenesis of AD by orchestrating the interactions between resident and infiltrating 
cells. In this thesis, it was shown that the expression of skin IL-6 and IL-1  mRNA was 
strongly decreased in the OVA-sensitized Smad3-/- mice compared to WT mice. 
 The interaction between IL-6 and TGF-  in disease states has been demonstrated by 
several studies. An intestinal epithelial cell line study demonstrated a cross-talk between 
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TGF-  and IL-6, and it suggested that TGF-beta may play a role in the negative regulation 
of IL-6 signalling in intestinal epithelial cells (Walia et al. 2003). Moreover, a study in 
proximal tubular cells revealed that IL-6 was able to increase TGF- 1 -dependent Smad3-
signaling.  The study suggested that synergistic effect between IL-6 and TGF- 1 might 
lead to an enhanced pro-fibrotic response in the kidney (Zhang et al. 2005). Furthermore, 
IL-1  -induced inflammation toward fibrosis was shown to be Smad3 dependent, because 
it developed only in WT control mice and not in Smad3 null mice (Bonniaud et al. 2005).
The role of TGF-  and factors affecting mast cell migration are largely unknown. In this 
thesis, the increased numbers of mast cells was found in the skin of OVA sensitized 
Smad3-/- mice suggesting that TGF- -Smad3 pathway regulates mast cell fate in the 
allergen sensitized skin. Mast cells, eosinophils, and other cells recruited to the site of 
inflammation, are potential sources of TGF- .  Smads appear to be involved in TGF- 1-
mediated mast cell migration and also TGF- 1-mediated mast cell growth inhibition since 
TGF- 1 has been shown to induce the migration of the human mast cell line at 40 fM, 
whereas growth inhibition of mast cells was detected at 400 pM (Olsson et al. 2001). 
Moreover, the signals induced by TGF- 1 that lead to cell migration appear to be different 
from the signals evoking growth inhibition in mast cells (Olsson et al. 2001). ). Funaba et 
al. suggested that TGF- -induced and Smad3-mediated signaling is essential for maximal 
cell growth in mast cells, and that the activin pathway may be required for it when mast 
cell context is modulated by Smad3 depletion (Funaba et al. 2006). 
The elevated levels of IgE and the severity of AD have been shown to correlate 
(Boguniewicz et al. 2006; Flohr et al. 2004). In this thesis, the OVA-specific IgE levels, 
but not OVA-specific IgG2a levels, were significantly upregulated in Smad3-/- mice 
compared to their WT controls after epicutaneous OVA sensitization. It seems that 
Smad3-signalling has an inhibitory effect on the production of allergen specific IgE in the 
model of AD used in the thesis. TGF-  is known to suppress IgE synthesis. Thus, 
impaired TGF- -Smad3 signalling may result in the upregulation of OVA-specific IgE 
antibodies. 
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9.2 TGF-  -signaling through Smad3 in the mouse models of allergic contact 
reactions (III, IV) 
TGF-  is known to be an important immunomodulatory factor in the progression of DTH 
reactions and ACD. TGF-  is crucial in regulating the cellular responses involved in 
contact allergy, such as differentiation, proliferation and migration. T regulatory cells, 
which produce both TGF-  and IL-10, might play a central role in inducing T cell anergy 
and active suppression leading to the attenuation of the ACD reaction. However, it is still 
not clear what are the mechanisms and how TGF-  functions nor is the role of TGF-  / 
Smad3 -signalling in the immunoregulation of DTH and contact dermatitis totally 
understood. In this thesis, the role of TGF-  / Smad3 -signalling in a murine model of 
contact hypersensitivity using Smad3 deficient knockout mice was investigated. Two 
types of allergens were studied, the contact allergen oxazolone and trimellitic anhydride, 
the respiratory allergen. TMA inducing stronger Th2, but weaker Th1 responses than 
OXA, amplified the proinflammatory, Th17 cytokine and regulatory component, TGF-
and Foxp3, respond similarly when Smad3 is lacking. It has been demonstrated that TGF-
 secretion inhibits the production of many inflammatory cytokines and chemokines in 
macrophages including IL-1 , TNF- , and IL-8 (McDonald et al. 1999). In this thesis, 
significantly increased production of proinflammatory cytokines in mice with TGF-  -
signalling deficiency was observed upon sensitization with oxazolone and TMA. IL-6 
shares functions with IL-1 and TNF- , but it also inhibits the synthesis of both of these 
factors (DiCosmo et al. 1994). It is known that adhesion molecules are inducible by 
stimulation with proinflammatory macrophage-derived cytokines (Bevilacqua, 1993). 
Furthermore, a certain degree of local trauma can induce or upregulate proinflammatory 
cytokines, which facilitate, or are required for, the optimal development of skin 
sensitization. It has been reported that hapten exposure can induce the secretion of 
proinflammatory cytokines IL-1 , TNF-  and IL-6 in the skin (Bonneville et al. 2007, 
Nakae et al. 2001, Enk and Katz, 1992). Dendritic cell-derived IL-1  is critical for the 
initiation of primary immune responses (Enk et al.1993), whereas almost exclusively mast 
cell derived TNF-  is essential for the recruitment of polymorphonuclear cells and tissue 
swelling during the effector phase of a CHS response (Biedermann et al.  2000). IL-6 is an 
important activator of T cells, mediator of acute phase reactions, and essential to the CHS 
response (Hope et al. 2000). IL-1 and TNF-  are known to be crucial, as demonstrated 
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by the impaired CHS in mice lacking these cytokines (Shornick et al. 1996, Pasparakis et
al. 1996). In this thesis, impaired TGF-  signalling due to the lack of Smad3, resulted in a 
significant increase in the expression of IL-1 , TNF-  and IL-6 in the skin during the 
CHS response to oxazolone and TMA. The expression of inflammatory cytokine mRNA 
was significantly increased also in the local draining lymph nodes of allergen sensitized 
Smad3-/- mice, although at less striking levels than observed in the skin. Since 
upregulation of proinflammatory cytokine facilitates or is required for the optimal genesis 
of skin sensitization, the results in this thesis suggest that TGF-beta/Smad3 –signalling is 
involved in the process of sensitization by regulating the expression of proinflammatory 
cytokines in the skin. 
The general view is that CHS is mediated by IFN-  producing CD8+ T cells, while IL-2, 
IL-4 and IL-10 producing CD4+ T cells regulate the response. However, there are also 
results pointing to an effector role for CD4+ T cell in the CHS response to oxazolone in 
C57BL6 mice (Xu et al. 1996). In addition, the Th2 type cytokine IL-4 might have a 
proinflammatory role, as shown by the report of impaired CHS responses in mice lacking 
IL-4 (Traidl et al. 1999). 
During the immune response to TMA, only low levels of Th1 type cytokines (IFN- ) are 
produced, whereas the expression of Th2 cytokines (IL-4) is comparatively high 
(Warbrick et al. 1998). In this thesis, the expressions of both IFN-  and IL-4 were greatly 
increased in the skin in Smad3-/- mice compared to WT mice after exposure to topical 
TMA, suggesting that Smad3 regulates the cytokine expression in both CD4+ and CD8+ T 
cells, modulating both Th1 and Th2 responses. The level of IL-4, but not IFN-  mRNA, 
was greatly increased also in the lymph nodes of Smad3-/- mice after topical TMA 
exposure. The level of IL-4 mRNA in the skin of Smad3-/- mice was strongly increased 
after exposure to oxazolone, while the expression of IFN-  remained at the same level in 
Smad3-/- mice as in their WT siblings. Thus, IFN-  production, presumably by CD8+ T 
cells in this model (Xu et al. 1996) is not affected by the lack of Smad3. In contrast, the 
production of IL-4, mainly by CD4+ T cells, according to previous findings (Xu et al.
1996), is strongly affected by the lack of Smad3. 
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In this thesis the proliferation of ear draining lymph node cells of TMA sensitized Smad3-
/- mice increased significantly compared to WT littermates. Also the size of ear draining 
lymph node was increased in TMA treated Smad3-/- mice compared to WT mice. A recent 
study claimed that Smad3 was essential for TGF-  blockade of IL-2 production in both 
CD4+ and CD8+ T cells. There is a report that although TGF-  inhibition of T cell 
receptor (TCR)-mediated CD4+ T cell proliferation was abrogated in Smad3-/- T cells, its 
inhibition of CD8+ T cell proliferation remained intact (Bevilacqua, 1993).  Thus, in 
CD8+ T cells, but not in CD4+ T cells, antiproliferative pathways are independent of IL-2 
and Smad3. The results in this thesis are in line with the previous data indicating that in 
WT mice, Smad3 is important for TGF-  inhibition of T cell proliferation. There was a 
slight tendency toward increased numbers of CD3+ and CD4+ cells in the skin of Smad3-
/- mice after oxazolone exposure contributing also to the increased expression of IL-4 
mRNA. 
 It was found that the defect in TGF-  -signalling increased significantly the mRNA 
expression of both CXCL5/LIX and CCL3/macrophage inflammation protein -1  (MIP-
1 ) in the skin of oxazolone or TMA treated Smad3-/- mice compared to the WT 
littermates. The results of the chemokine expression reflected the recruitment of 
neutrophils in the murine model of contact hypersensitivity. Elevated concentrations of 
CCL3/MIP-1  and IL-8 have previously been linked to hypersensitivity pneumonitis, an 
inflammatory lung disease characterized by the presence of CD8+ T cells and neutrophils 
(Denis, 1995). Murine CXCL5/LIX is a close homolog of human epithelial cell-derived 
neutrophil attractant-78 (ENA-78, CXCL5) and granulocyte chemotactic protein-2 (GCP-
2, CXCL6) (Smith and Herschman, 2004). ENA-78, GCP-2, and IL-8 have been shown to 
be necessary in the chemotaxis of neutrophils (Rudack et al. 2003). IL-8 is one of the most 
potent chemoattractants for neutrophils. In addition to CCL3/MIP-1 , IL-8 is a powerful 
stimulating agent for polymorphonuclear neutrophil leukocytes (PMN) (Horuk, 1995). 
CCL3/MIP-1  is a member of the C-C chemokine supergene family (Schall and Bacon, 
1994, Zlotnik et al. 1999). Like other members of this family, CCL3/MIP-1  promotes the 
recruitment of mononuclear phagocytes and lymphocytes (Schall et al. 1993, Taub et al.
1993). CCL3/MIP-1  has also been reported to be chemotactic for neutrophils both in vivo
and in vitro (Appelberg, 1992). There is a transient appearance of neutrophils at the site of 
inflammation. After the neutrophils, macrophages participate in the inflammatory 
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response; they are attracted to the inflammatory site by chemotaxis in the same way as 
neutrophils. Werner et al. showed in vitro that TGF-  could inhibit the expression of the 
inflammatory chemokine CCL3/MIP-1  (Werner et al. 2000). The study also suggested 
that the inhibition of macrophage activation by TGF-  was mediated via Smad3 (Werner 
et al. 2000). This is in line with our result of decreased expression of CCL3/MIP-1  in the 
mice with deficiensy of TGF-  -signalling. Thus TGF-  / Smad3 -signalling seems to be 
involved in the regulation of chemotaxis to the site of inflammation. 
A recent study suggested a novel role for neutrophils as a source of T cell-recruiting 
chemokines CXCL10/IP-10 and CXCL9/MIG during the DTH response (Molesworth-
Kenyon et al. 2005). The CXCR3 activating chemokines CXCL10/IP-10 and 
CXCL9/MIG have been shown to be expressed in allergic but not in irritant patch test 
reactions (Flier et al. 1999). In this thesis, significantly elevated levels of CXCL9/MIG 
and CXCL10/IP-10 mRNA were detected in the skin of TMA sensitized mice compared to 
the control littermates. However, no difference was observed in the expression levels 
between WT and Smad3-/- mice. The trend reflects the amount of neutrophils detected in 
this study. 
Significantly increased mRNA expression of a major Th2 cytokine IL-4, Th2 related 
chemokine CCL24/eotaxin-2 and its receptor CCR3, which is expressed predominantly on 
eosinophils, was observed in the skin of oxazolone challenged Smad3-/- mice compared to 
WT mice in this thesis. The result may contribute to the increased infiltration of 
eosinophils seen in the skin of Smad3-/- mice although the difference was not significant. 
Not only eosinophils but also Th2 lymphocytes and basophils, cells that are important in  
allergic inflammation, express the CCR3 receptor (Sallusto et al. 1997). Therefore CCR3 
ligands, such as CCL24, may further amplify the Th2 response in allergic inflammation. 
In contrast to enhanced Th2 response, the mRNA expression of Th1 related IFN- and 
Th1 linked chemokines CXCL9/MIG and CXCL10/IP-10 were unaltered by the lack of 
Smad3 in the oxazolone induced contact hypersensitivity response. The present results 
suggest that TGF- /Smad3 signaling regulates differently Th1 and Th2 type immune 
responses. It is possible that Th1 differentiation is more resistant to TGF- mediated 
inhibition compared to Th2 differentiation. The exact mechanism of the elevated Th2 type 
response in the absence of Smad3 however, remains unresolved. 
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Two chemokines, CCL3 the expression of which is inhibited by TGF-  (Werner et al.
2000) and CXCL5, promote the recruitment of neutrophils (Appelberg 1992), which in 
turn produce the T cell-recruiting chemokines CXCL9 and CXCL10 (Molesworth-Kenyon 
et al. 2005). These chemokines are highly expressed during the CHS response (Flier et al.
1999). In this thesis, CCL3 and CXCL5 mRNA levels in the skin of TMA treated Smad3-
/- were greatly increased, and the number of neutrophils was slightly, but not statistically 
significantly increased in the skin of Smad3 deficient mice. The expression levels of 
CXCL9 and CXCL10 mRNA were equally increased in the skin of TMA exposed Smad3-
/- and WT mice. These results suggest that Smad3 is involved in regulating the 
chemoattraction of neutrophils during the contact sensitivity response to TMA.              
IL-4 has been reported to have an important regulatory effect on the CHS responses 
(Asada et al. 1997, Weigmann et al. 1997). Xu et al demonstrated that IL-4/IL-10 –
secreting cells negatively regulate CHS response (Xu et al. 1996). It has been 
demonstrated to block CHS by the inhibition of Langerhans cell migration induced by 
TNF-  (Takayama et al. 1999). Interestingly, in this thesis the expression of skin IL-4 
mRNA was increased in the oxazolone and TMA sensitized skin of Smad3-/- mice 
compared to WT mice. Significantly increased levels of IL-4 and IL-10 mRNA were 
detected in draining lymph nodes of the ear of oxazolone treated WT mice compared to 
the WT controls. Instead, in unsensitized Smad3-/- mice, the expression of IL-4 and IL-10 
mRNA was increased. Although the expression levels were increased after oxazolone 
treatment, no significant differences between sensitized and control Smad3-/- ear draining 
lymph nodes were detected. Kitani et al demonstrated that TGF-  -producing regulatory T 
cells can induce Smad mediated IL-10 secretion and this effect is particularly intense 
under Th1 conditions (Kitani et al. 2003). In addition to IL-4, also Th1 cytokine, IFN- ,
and IL-17 were significantly increased in TMA sensitized Smad3-/- mice compared to WT 
mice. The skin of oxazolone sensitized Smad3-/- mice expressed increased IL-4 and IL-17 
mRNA. Several reports have described that IL-17 can induce the mobilization, recruitment 
and activation of neutrophils and trigger the production of proinflammatory cytokines and 
chemokines thereby coordinating local tissue inflammation (Acosta-Rodriquez et al. 2007, 
Kolls and Lindén, 2004). Recent studies have suggested that TGF-  together with IL-6 can 
mediate the development of IL-17-producing T cells from naive precursors (Veldhoen et
al. 2006, Bettelli et al. 2006, Mangan et al. 2006).
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TGF-  induces its own gene expression (McCartney-Francis et al. 1990). Smad3 plays an 
important role in the autoregulation of TGF-  expression in fibroblasts and keratinocytes 
(Ashcroft et al. 1999, Piek et al. 2001). In the studies of Ashcroft and Piek, Smad3 mutant 
cells were unable to upregulate their TGF-  expression in response to TGF- in vitro. In 
the lung, however, a lack of Smad3 was not able to prevent bleomycin-induced 
upregulation of TGF- in vivo (Zhao et al. 2002).
In this thesis, Smad3 deficiency significantly augmented TGF-  expression in the skin. 
TGF-  is important for T regulatory cell (Treg) differentiation, maintenance and function 
(Marie et al. 2005) and some studies have implicated TGF-  in the inhibitory mechanisms 
of Tregs in CHS reactions (Szczepanik et al. 2005).
In this thesis, the level of the mRNA expression of TGF-  as well as Foxp3, Treg lineage 
specific transcriptor factor, was significantly increased in Smad3 deficient skin after 
topical oxazolone exposure. Treg cells potently suppress T-cell activation. A dysfunction 
of forkhead box P3 (Foxp3), which controls Treg lineage development, leads to reduced 
numbers of Treg cells and breaking of immune tolerance, causing aggressive multi-organ 
autoimmune pathology, often associated with skin inflammation (Dearman and Kimber, 
2001, Massague 2000). In mice, depletion of Treg cells has been reported to evoke an 
enhanced and prolonged Th1-mediated delayed-type hypersensitivity response (Massague, 
2000) and adoptive transfer of suppressive Treg cells can reduce the pathology of contact 
hypersensitivity (Ring et al. 2006). 
The expression of another important regulatory cytokine, IL-10 (Hawrylowicz and 
O'Garra, 2005, Taylor et al. 2005, Maurer et al. 2003), a product of regulatory dendritic 
cells and Tregs was, however, unaffected by the lack of Smad3. In contrast, topical 
application of TMA reduced significantly the expression of Foxp3 mRNA in the skin and 
in the lymph nodes of WT and Smad3 deficient mice. 
It was shown in this thesis that TMA-specific IgE levels were increased both in Smad3-/- 
and WT mice, whereas the level of TMA-specific IgG2a was significantly decreased in 
Smad3-/- mice compared to their WT littermates. One possible explanation for this 
phenomenon is the sharp increase in IL-4 production in the Smad3-/- mice, while IFN-
expression remained at a low level both in the lymph nodes and in the skin. The levels of 
IgG2a and IgE reflect the Th1 and Th2 responses. The regulation of antibody responses is 
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of crucial importance in the development of allergy. Although there are many factors that 
affect antibody production, the predominant signals are provided by Th1 and Th2 
cytokines (Dearman and Kimber, 2001). The initiation and maintenance of the IgE 
response is dependent on IL-4, while IFN-  antagonizes the production of IgE. The 
balance between Th1 and Th2 type cytokines also influences the IgG2a response. It has 
been suggested that the Th1 type response promotes CHS whereas type 2 down-regulates 
the CHS response (Asada et al. 1997). Thus, Smad3 / TGF-  signalling participates in the 
modulation of the inflammatory hypersensitivity reaction and disease progression through 
the regulation of the specific antibody response. 
Taken together, TGF-  / Smad3 -signaling evokes a wide spectrum of effects in the 
immune responses of contact allergy. The results in this thesis demonstrate that TGF-  / 
Smad3 -signalling affects the expression of proinflammatory, Th1 and Th2 cytokines and 
is involved in the recruitment of cells to the site of inflammation via chemokine secretion. 
A Smad3 deficiency increases the mRNA expression of CCL3/MIP-1  and CXCL5/LIX 
in the skin; the increase in these levels correlates with the recruitment of neutrophils in a 
murine model contact hypersensitivity. The data in this thesis indicates that in WT mice, 
Smad3 is essential for TGF-  inhibition of T cell proliferation, but in Smad3-/- mice TGF-
 is not able to inhibit the proliferation of the T cell subset. TGF-  -signalling modulates 
Th2 cytokine secretion in the skin and draining lymph nodes of the ear and participates 
importantly in the regulation of CHS responses. The data demonstrate also that Smad3 can 
regulate the specific antibody response.
9.3 TGF-  -signaling through Smad3 in the mouse model of asthma 
TGF-  is thought to be involved in the development of subepithelial fibrosis, and TGF-
has a major role in the remodelling of the airway wall in bronchial asthma. TGF-
signalling has been shown to be active in asthmatic airways and the activity is associated 
with the development of airway remodelling in asthma (Sagara et al. 2002). A reduced 
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expression of TGF- 1 has been associated with an increased eosinophilic inflammation 
and elevated mucus secretion in response to ovalbumin sensitization (Scherf et al. 2005).
In this thesis, it was found that the lack of Smad3-/- signalling led to an exaggerated 
asthmatic phenotype in an allergic asthma model. The exaggerated asthmatic phenotype 
seen  resembled that reported in the work of Nakao et al  (Nakao et al. 2000) where 
expression of the inhibitory Smad7 was used to disturb the signalling. 
Smad3-/- and WT mice both demonstrated an inflammatory response and, in addition, 
Smad3-/- mice showed an amplified AHR response to ovalbumin sensitization/challenge 
in the murine model of asthma used in the thesis. Ovalbumin-specific IgG1 levels were 
significantly increased in the serum of ovalbumin sensitized Smad3-/- mice compared to 
the corresponding values in WT mice. The productions of ovalbumin-specific IgE and 
IgG2a were unaffected by the lack of Smad3, the concentrations were similarly increased 
in the serum of ovalbumin sensitized Smad3-/- and WT mice. Although the levels of 
IgG2a were lower in Smad3-/-, the difference was not statistically significant. 
Airway hyperreactivity (AHR) in response to the value reflecting methacholine sensitivity, 
PenH pdc, tended to be higher in OVA-sensitized Smad3-/- mice compared to OVA-
sensitized WT mice. Signs of respiratory distress after allergen exposure were observed in 
Smad3-/- but not in WT mice. However, the differences between groups were not clearly 
statistically different. This might be explained by the characteristics, as reported earlier 
(Drazen et al. 1996), of the C57BL/6 mouse strain. C57BL/6 mice are more resistant to 
bronchoconstrictor agents and differences between mice might be difficult to observe with 
this method. 
Th2 cytokines IL-13, IL-5 and IL-4 are closely related to the pathology in asthma. They 
all play a crucial role in a development of inflammation in this disease. The results in this 
thesis provide evidence that Smad3 deficiency significantly reduced the expression of IL-
13 mRNA in the lung of ovalbumin sensitized allergic mice in the murine asthma model 
used. The expression of IL-5 was also diminished in the lungs of the ovalbumin sensitized 
Smad3-/- mice compared to WT mice. Instead, the differences were not detected in the IL-
4 mRNA levels between the OVA sensitized Smad3-/- and WT mice. IL-13 is known to 
have a central role in the effector phases of the Th2 inflammation. IL-13 is a potent 
inducer of tissue inflammation, airway hyperresponsiveness (AHR), and mucus 
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hyperproduction (Zhu et al. 1999). It has been reported that IL-13 can stimulate airway 
fibrosis through the action of matrix metalloproteinases on TGF-  and promote epithelial 
damage and eosinophilia (Cohn et al. 2004). 
IL-4 is believed to have an important role in the regulation of eosinophilia, AHR and 
mucus production (Corry 1999). In contrast, blockade of IL-13 signalling was reported to 
cause a weakening of these features (Grunig et al. 1998).  In this thesis, Smad3 deficient 
mice with diminished IL-13 production clearly exhibited increased airway hyperreactivity 
and substantially increased mucus production. This result is in agreement with the finding 
of Perkins et al (Perkins et al. 2006) who demonstrated a role for IL-4 in promoting all the 
Th2 tissue responses independent of IL-13. 
In this thesis, the PAS positive cells were increased in the lung of Smad3-/- mice. The 
PAS positive cells were detected also in the lung of naive, unsensitized Smad3-/- mice. 
The results indicate that the TGF- /Smad3 -signalling is an important to the IL-13 -
signalling pathway, and also that TGF- /Smad3 -signalling mediates mucus production 
and is able to inhibit PAS production. In contrast to the results in this thesis, the study by 
Le et al (Le et al. 2007) indicated that Smad3 deletion could lead to a decrease in mucin 
production and eosinophilia whereas no changes with the AHR were detected. However, 
in the study by Le et al, the Smad3 deletion differed from that used in this thesis i.e. exons 
2 (Zhu et al.1998), instead of exons 8 (Yang et al. 1999), were deleted on both alleles. 
These different Smad3 deletions often give contradictory results. It has been suggested 
that some part of the mutant transcript (exons 4-9) could be translated in the Smad3 (exon 
2) deletion, while in the Smad3 (exon 8) deletion no part of the mutant transcript is 
translated (Yang et al. 1999). Thus, the explanation for the differences between the results 
in this thesis and the study by Le et al might be that some part of Smad3 had been 
translated in the latter experiments. The other models utilizing manipulated TGF- or its 
receptor report very similar results to the data in this thesis concerning the inflammatory 
state i.e. eosinophilia, mucin production, and AHR is increased when TGF-  - levels or 
effect is decreased (Scherf et al. 2005, Nakao et al. 2000).
The transcription factor, GATA-3, is reported to be the master Th2 regulatory factor and 
important for Th2-type cytokine production (Zheng and Flavell, 1997, Zhu et al. 2004). A 
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recent study reported that GATA-3 directly could interact with Smad3, and that GATA-3 
can mediate the recruitment of Smad3 to GATA binding site. It has been claimed that the 
two factors cooperate synergistically to regulate transcription from the Il-5 promoter in a 
TGF- -dependent manner (Blokzijl et al. 2002). This could explain the result in this thesis 
of higher IL-5 levels in the lung of OVA sensitized WT mice compared to OVA sensitized 
Smad3-/- mice. A higher mRNA level of IL-13 in the OVA sensitized WT mice compared 
to Smad3-/- mice was also detected. Indeed, it has been shown that there are GATA-3-
binding sites in the Il-13 promoters, but not in the Il-4 promoter (Lavenu-Bombled et al.
2002, Kishikawa et al. 2001, Yamashita et al. 2002). In the thesis, the mRNA level of 
GATA-3 was determined in the lung. GATA-3 expression was slightly increased in OVA 
sensitized WT mice, but not in Smad3-/- mice. It has been reported that a defect in GATA-
3 could attenuate allergic inflammation in a murine model of asthma, with decreased 
eosinophilia, reduced mucus production, and decreased IL-4, IL-5, and IL-13 production 
(Zhang et al. 1999). Similarly, intranasal administration of antisense DNA to GATA-3 
reduced airway inflammation, mucus production, and hyperresponsiveness in a murine 
model of asthma (Finotto et al. 2001). It is shown that the deletion of GATA-3 from 
established Th2 cells abolished IL-5 and IL-13, but not IL-4 production (Zhu et al. 2004). 
Recently, it was demonstrated that GATA-3 can promote Th2 responses through different 
mechanisms, in collaborating with other transcription factors (Zhu et al. 2006). However, 
there are unknown factors or mechanisms and it is still not known whether Smad3 and 
GATA-3 cooperate to regulate transcription from the Il-13 promoter in a TGF- -
dependent manner. The findings in this thesis point to a critical dependence on GATA-3 in 
the way that Smad3 regulates IL-13 expression. 
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Table 4 Summary of main results using Smad3-/- mice and different experimental 
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10. SUMMARY AND CONCLUSIONS 
In this thesis, the role of the TGF- -Smad -signalling pathway was examined by using 
Smad3 -deficient mice and evaluated in several murine models of allergic diseases, atopic 
dermatitis, asthma and contact dermatitis.  
In a murine model of atopic dermatitis, the epicutaneous application of ovalbumin (OVA) 
applied via a patch to tape-stripped skin was used to induce dermatitis in mice (I). The 
thickness of the dermis was significantly reduced in OVA-sensitized skin of Smad3-/- 
mice. The defect in the dermal thickness was accompanied with the decrease in the 
expression of mRNA for proinflammatory cytokines IL-6 and IL-1  in the OVA-
sensitized skin. In contrast, the number of mast cells was significantly increased in OVA 
sensitized skin of Smad3-/- mice and they also exhibited elevated levels of OVA-specific 
IgE.
The role of TGF-  signalling for the T-helper2 (Th2) cytokine homeostasis in normal 
lungs and for the regulation of inflammation in a murine model of asthma was studied 
using mice deficient for Smad3. Allergic airway disease was induced in Smad3 knock-out 
and wild type mice by sensitizing them by intraperitoneal injections with ovalbumin 
(OVA), and challenging later with aerosolized ovalbumin (II). Compared to wild type 
mice, naive (unmanipulated) Smad3-/- mice exhibited significantly increased levels of 
proinflammatory and Th2 cytokines as well as Th2 associated transcription factor GATA-
3 in the lung tissue and bronchoalveolar lavage (BAL). In the asthma model, mucin 
secretion and airway hyperresponsiveness (AHR) after allergen exposure were 
significantly increased in the Smad3-/- mice as compared to WT mice. IL-4 levels were 
equally elevated but IL-13 levels were decreased in the airways of OVA sensitized 
Smad3-/- mice compared to controls. However, the expressions of IL-4 mRNA and 
protein were significantly increased in PBS treated Smad3-/- mice. In line with this, the 
cell counts of saline PBS sensitized mice were higher in Smad3-/- mice and there was an 
increase in the numbers of eosinophils and neutrophils. 
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In the contact hypersensitivity studies (CHS) the skin and ears of Smad3 mice were treated 
with contact allergen, oxazolone (III), or respiratory allergen (IV), trimellitic acid 
anhydride (TMA). 
Topical exposure to oxazolone induced a significantly increased expression of CCL3/MIP-
1  and CXCL5/LIX accompanied by increased neutrophil infiltration in the skin of Smad3 
deficient mice when compared to their wild type siblings. Also the mRNA expression for 
CCL24/eotaxin-2, pro-inflammatory cytokines IL-6, IL-1  and TNF- as well as Th2 
type cytokine IL-4 were significantly increased in Smad3-/- mice compared to wild type 
mice. Furthermore, topical exposure to oxazolone induced significantly increased 
expression of TGF-  and Foxp3 mRNA in Smad3-/- mice. However, the expressions of 
Th1 cytokine IFN- , as well as Th1 type chemokines CXCL9/MIG and CXCL10/IP-10 
were unaffected by the lack of Smad3, and the ear swelling responses to topically applied 
oxazolone were similar in Smad3 knockout mice compared to wild type mice.  
The defect in TGF- /Smad3 -signaling promoted the secretion of the proinflammatory, 
Th1 and Th2 cytokines after topical exposure to TMA. Also the expression of IL-17 
mRNA in the skin of TMA sensitized Smad3-/- mice was increased indicating that Smad3 
may be involved in the progress of tissue inflammation via IL-17. In contrast to the 
situation with the contact allergen OXA, the respiratory allergen TMA did not induce 
Foxp3 expression. The shifted Th1/Th2 balance due to Smad3 deficiency during the CHS 
response to TMA, also caused modulated antibody class switching.
Furthermore, the mRNA expressions of chemokines contributing to the leukocyte 
recruitment, CCL3/MIP-1  and CXCL5/LIX, were upregulated in Smad3-/- mice. The 
data in the thesis is in line with the previous data suggesting that in wild type mice, Smad3 
is essential for TGF-  inhibition of T cell proliferation, but in Smad3-/- mice TGF-  is not 
able to inhibit the proliferation of the T cell subset. This data suggests also that Smad3 
regulates the specific antibody response.
In conclusion, Smad3-pathway regulates allergen induced skin inflammation and systemic 
IgE antibody production in a murine model of AD. TGF-  / Smad3 -signalling contributed 
to inflammatory hypersensitivity reactions and disease progression via modulation of 
chemokine and cytokine expression, regulation of specific antibody response and 
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inflammatory cell recruitment in a murine model of CHS. The defect in Smad3 -signalling 
decreased the expressions of IL-13 and IL-5 mRNA in the lung, modulated allergen 
induced specific IgG1 response, and affected mucus production in the lung in a murine 
model of asthma. 
In summary, TGF-  can modulate inflammatory responses - at least partly through the 
Smad3 pathway - but also through other compensatory, non-Smad-dependent pathways. 
The Smad3 signalling pathway might be a potential target in the therapy of allergic skin 
diseases. Unravelling the mechanisms of Smad3 may open new possibilities for treating 
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